

# Josep-Maria Ribera

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7680307/publications.pdf>

Version: 2024-02-01

524  
papers

19,266  
citations

14614

66  
h-index

18606

119  
g-index

603  
all docs

603  
docs citations

603  
times ranked

17375  
citing authors

#	ARTICLE	IF	CITATIONS
1	Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. <i>New England Journal of Medicine</i> , 2017, 376, 836-847.	13.9	1,443
2	Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2015, 16, 57-66.	5.1	1,031
3	Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. <i>Lancet Oncology</i> , The, 2010, 11, 934-941.	5.1	427
4	Mantle cell lymphoma. , 1998, 82, 567-575.		302
5	Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. <i>Leukemia</i> , 2010, 24, 521-535.	3.3	302
6	High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. <i>Blood</i> , 2005, 106, 3755-3759.	0.6	298
7	Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. <i>Blood</i> , 2010, 115, 5137-5146.	0.6	278
8	Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2016, 27, v69-v82.	0.6	268
9	Peripheral T-cell lymphomas: Initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification. <i>Annals of Oncology</i> , 1998, 9, 849-855.	0.6	264
10	Influence of Pre- and Post-Transplantation Responses on Outcome of Patients With Multiple Myeloma: Sequential Improvement of Response and Achievement of Complete Response Are Associated With Longer Survival. <i>Journal of Clinical Oncology</i> , 2008, 26, 5775-5782.	0.8	263
11	Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy. <i>Blood</i> , 2013, 121, 2734-2738.	0.6	246
12	Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-“positive ALL. <i>Blood</i> , 2016, 128, 774-782.	0.6	243
13	Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group. <i>Haematologica</i> , 2010, 95, 589-596.	1.7	240
14	Comparison of the Results of the Treatment of Adolescents and Young Adults With Standard-Risk Acute Lymphoblastic Leukemia With the Programa Español de Tratamiento en Hematología Pediatric-Based Protocol ALL-96. <i>Journal of Clinical Oncology</i> , 2008, 26, 1843-1849.	0.8	239
15	Treatment of High-Risk Philadelphia Chromosome-“Negative Acute Lymphoblastic Leukemia in Adolescents and Adults According to Early Cytologic Response and Minimal Residual Disease After Consolidation Assessed by Flow Cytometry: Final Results of the PETHEMA ALL-AR-03 Trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 1595-1604.	0.8	227
16	Sustained Remissions of High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome After Reduced-Intensity Conditioning Allogeneic Hematopoietic Transplantation: Chronic Graft-Versus-Host Disease Is the Strongest Factor Improving Survival. <i>Journal of Clinical Oncology</i> , 2008, 26, 577-584.	0.8	213
17	Effect of using reporting guidelines during peer review on quality of final manuscripts submitted to a biomedical journal: masked randomised trial. <i>BMJ: British Medical Journal</i> , 2011, 343, d6783-d6783.	2.4	210
18	Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Espanol de Linfomas/Trasplante de Medula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. <i>Haematologica</i> , 2012, 97, 310-317.	1.7	194

#	ARTICLE	IF	CITATIONS
19	Prognostic Value of Immunophenotyping in Multiple Myeloma: A Study by the PETHEMA/GEM Cooperative Study Groups on Patients Uniformly Treated With High-Dose Therapy. <i>Journal of Clinical Oncology</i> , 2008, 26, 2737-2744.	0.8	193
20	Bone Marrow Changes in Anorexia Nervosa Are Correlated With the Amount of Weight Loss and Not With Other Clinical Findings. <i>American Journal of Clinical Pathology</i> , 2002, 118, 582-588.	0.4	185
21	Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. <i>Annals of Oncology</i> , 2008, 19, 958-963.	0.6	182
22	Decay rates for viscoelastic plates with memory. <i>Journal of Elasticity</i> , 1996, 44, 61-87.	0.9	169
23	Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis. <i>Leukemia</i> , 2007, 21, 143-150.	3.3	167
24	Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial. <i>Haematologica</i> , 2010, 95, 87-95.	1.7	164
25	Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2002, 119, 976-984.	1.2	163
26	Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients. <i>Blood</i> , 2013, 122, 3251-3262.	0.6	156
27	International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia. <i>Haematologica</i> , 2016, 101, 1524-1533.	1.7	154
28	Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. <i>Leukemia</i> , 2006, 20, 35-41.	3.3	149
29	Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial. <i>Blood</i> , 2012, 120, 2581-2588.	0.6	148
30	Differences of peripheral inflammatory markers between mild cognitive impairment and Alzheimer's disease. <i>Immunology Letters</i> , 2008, 117, 198-202.	1.1	142
31	Peripheral levels of glutathione and protein oxidation as markers in the development of Alzheimer's disease from Mild Cognitive Impairment. <i>Free Radical Research</i> , 2008, 42, 162-170.	1.5	136
32	Nonmyeloablative Stem Cell Transplantation Is an Effective Therapy for Refractory or Relapsed Hodgkin Lymphoma: Results of a Spanish Prospective Cooperative Protocol. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 172-183.	2.0	135
33	Comparable survival between HIV+ and HIV- non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell transplantation. <i>Blood</i> , 2009, 113, 6011-6014.	0.6	131
34	Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial. <i>Haematologica</i> , 2005, 90, 1346-56.	1.7	129
35	Allogeneic Transplant with Reduced Intensity Conditioning Regimens may Overcome the Poor Prognosis of B-Cell Chronic Lymphocytic Leukemia with Unmutated Immunoglobulin Variable Heavy-Chain Gene and Chromosomal Abnormalities (11q <sup>23</sup> and 17p <sup>13</sup> ). <i>Clinical Cancer Research</i> , 2005, 11, 7757-7763.	3.2	124
36	Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin's lymphoma. <i>Haematologica</i> , 2007, 92, 191-198.	1.7	124

#	ARTICLE	IF	CITATIONS
37	High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma. <i>Cancer</i> , 2008, 113, 117-125.	2.0	122
38	Risk factors and outcome of COVID-19 in patients with hematological malignancies. <i>Experimental Hematology and Oncology</i> , 2020, 9, 21.	2.0	119
39	Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease. <i>Haematologica</i> , 2007, 92, 1489-1494.	1.7	116
40	Autologous Stem-Cell Transplantation in Patients With HIV-Related Lymphoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 2192-2198.	0.8	116
41	Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens. <i>Blood</i> , 2011, 117, 1799-1805.	0.6	112
42	Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial. <i>British Journal of Haematology</i> , 2008, 140, 411-419.	1.2	107
43	What Should the Age Range Be for AYA Oncology?. <i>Journal of Adolescent and Young Adult Oncology</i> , 2011, 1, 3-10.	0.7	106
44	Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). <i>Bone Marrow Transplantation</i> , 2019, 54, 798-809.	1.3	106
45	Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes. <i>British Journal of Haematology</i> , 2007, 139, 70-80.	1.2	104
46	Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia. <i>Blood Cancer Journal</i> , 2016, 6, e473-e473.	2.8	101
47	Acute myeloid leukemia with MLL rearrangements: clinicobiological features, prognostic impact and value of flow cytometry in the detection of residual leukemic cells. <i>Leukemia</i> , 2003, 17, 76-82.	3.3	99
48	Evaluation of procalcitonin, neopterin, C-reactive protein, IL-6 and IL-8 as a diagnostic marker of infection in patients with febrile neutropenia. <i>Leukemia and Lymphoma</i> , 2008, 49, 1752-1761.	0.6	98
49	Comparison of outcomes after single or double cord blood transplantation in adults with acute leukemia using different types of myeloablative conditioning regimen, a retrospective study on behalf of Eurocord and the Acute Leukemia Working Party of EBMT. <i>Leukemia</i> , 2014, 28, 779-786.	3.3	95
50	Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1739-1751.	1.9	87
51	Hodgkin's disease in patients with antibodies to human immunodeficiency virus a study of 22 patients. <i>Cancer</i> , 1990, 65, 2248-2254.	2.0	86
52	Influence of highly active anti-retroviral therapy on response to treatment and survival in patients with acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma treated with cyclophosphamide, hydroxydoxorubicin, vincristine and prednisone. <i>British Journal of Haematology</i> , 2001, 112, 909-915.	1.2	86
53	Medical syncretism with reference to malaria in a Tanzanian community. <i>Social Science and Medicine</i> , 2002, 55, 403-413.	1.8	85
54	HIV-associated lymphoma successfully treated with peripheral blood stem cell transplantation. <i>Experimental Hematology</i> , 2005, 33, 487-494.	0.2	83

#	ARTICLE	IF	CITATIONS
55	Veno-Occlusive Disease of the Liver after High-Dose Cytoreductive Therapy with Busulfan and Melphalan for Autologous Blood Stem Cell Transplantation in Multiple Myeloma Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 1448-1454.	2.0	83
56	CTLA-4 polymorphisms and clinical outcome after allogeneic stem cell transplantation from HLA-identical sibling donors. <i>Blood</i> , 2007, 110, 461-467.	0.6	82
57	Risk factors for, and clinical relevance of, faecal extended-spectrum $\beta$ -lactamase producing <i>Escherichia coli</i> (ESBL-EC) carriage in neutropenic patients with haematological malignancies. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2011, 30, 355-360.	1.3	82
58	Changes in the influence of lymphoma- and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphoma. <i>Annals of Oncology</i> , 2015, 26, 958-966.	0.6	81
59	Characteristics and Outcome of AIDS-Related Hodgkin Lymphoma Before and After the Introduction of Highly Active Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 47, 422-428.	0.9	79
60	Hepatosplenic T-Gammadelta Lymphoma in a Patient with Crohn's Disease Treated with Azathioprine. <i>Leukemia and Lymphoma</i> , 2003, 44, 531-533.	0.6	78
61	The lincRNA<i>HOTAIRM1</i>, located in the<i>HOXA</i> genomic region, is expressed in acute myeloid leukemia, impacts prognosis in patients in the intermediate-risk cytogenetic category, and is associated with a distinctive microRNA signature. <i>Oncotarget</i> , 2015, 6, 31613-31627.	0.8	78
62	Neutrophils of Centenarians Show Function Levels Similar to Those of Young Adults. <i>Journal of the American Geriatrics Society</i> , 2008, 56, 2244-2251.	1.3	75
63	Statistical Reviewers Improve Reporting in Biomedical Articles: A Randomized Trial. <i>PLoS ONE</i> , 2007, 2, e332.	1.1	75
64	Therapy-Related Myeloid Neoplasms in Patients With Acute Promyelocytic Leukemia Treated With All-<i>Trans</i>-Retinoic Acid and Anthracycline-Based Chemotherapy. <i>Journal of Clinical Oncology</i> , 2010, 28, 3872-3879.	0.8	74
65	â€œIt Is Me Who Endures but My Family That Suffersâ€: Social Isolation as a Consequence of the Household Cost Burden of Buruli Ulcer Free of Charge Hospital Treatment. <i>PLoS Neglected Tropical Diseases</i> , 2008, 2, e321.	1.3	73
66	COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA. <i>Blood</i> , 2022, 139, 1588-1592.	0.6	70
67	Acute Lymphoblastic Leukemia in Adolescents and Young Adults. <i>Hematology/Oncology Clinics of North America</i> , 2009, 23, 1033-1042.	0.9	69
68	Detection and outcome of occult leptomeningeal disease in diffuse large B-cell lymphoma and Burkitt lymphoma. <i>Haematologica</i> , 2014, 99, 1228-1235.	1.7	69
69	Recombinant alpha 2-interferon in the treatment of B chronic lymphocytic leukemia in early stages. <i>Blood</i> , 1988, 71, 1295-1298.	0.6	68
70	The paradox of the cost and affordability of traditional and government health services in Tanzania. <i>Health Policy and Planning</i> , 2000, 15, 296-302.	1.0	67
71	The European Hematology Association Roadmap for European Hematology Research: a consensus document. <i>Haematologica</i> , 2016, 101, 115-208.	1.7	67
72	Clinical significance of the presence of myeloid associated antigens in acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 1990, 75, 202-207.	1.2	66

#	ARTICLE	IF	CITATIONS
73	Doctors and Vampires in Sub-Saharan Africa: Ethical Challenges in Clinical Trial Research. <i>American Journal of Tropical Medicine and Hygiene</i> , 2014, 91, 213-215.	0.6	66
74	Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia. <i>European Journal of Haematology</i> , 2006, 78, 061114074547002-???	1.1	63
75	Dose-intensive chemotherapy including rituximab in Burkitt's leukemia or lymphoma regardless of human immunodeficiency virus infection status. <i>Cancer</i> , 2013, 119, 1660-1668.	2.0	63
76	FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk. <i>Annals of Oncology</i> , 2015, 26, 2155-2161.	0.6	63
77	Genomic polymorphisms provide prognostic information in intermediate-risk acute myeloblastic leukemia. <i>Blood</i> , 2006, 107, 4871-4879.	0.6	62
78	Central nervous system recurrence in adult patients with acute lymphoblastic leukemia. <i>Cancer</i> , 2006, 106, 2540-2546.	2.0	60
79	Bone marrow WT1 levels at diagnosis, post-induction and post-intensification in adult de novo AML. <i>Leukemia</i> , 2013, 27, 2157-2164.	3.3	60
80	Prognosis of AIDS-Related Systemic Non-Hodgkin Lymphoma Treated With Chemotherapy and Highly Active Antiretroviral Therapy Depends Exclusively on Tumor-Related Factors. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 44, 167-173.	0.9	59
81	Sirolimus as Part of Immunosuppressive Therapy for Refractory Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 701-706.	2.0	59
82	Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation. The GELTAMO experience. <i>European Journal of Haematology</i> , 2007, 78, 290-296.	1.1	59
83	Outcome and Prognostic Factors in Patients with Hematologic Malignancies Admitted to the Intensive Care Unit: A Single-Center Experience. <i>International Journal of Hematology</i> , 2007, 85, 195-202.	0.7	59
84	Immunohistochemical detection of MYC protein correlates with MYC gene status in aggressive B cell lymphomas. <i>Histopathology</i> , 2011, 59, 672-678.	1.6	59
85	MicroRNA expression at diagnosis adds relevant prognostic information to molecular categorization in patients with intermediate-risk cytogenetic acute myeloid leukemia. <i>Leukemia</i> , 2014, 28, 804-812.	3.3	59
86	Low perception of malaria risk among the Ra-glai ethnic minority in south-central Vietnam: implications for forest malaria control. <i>Malaria Journal</i> , 2010, 9, 23.	0.8	58
87	Hospitalizations for Ambulatory Care Sensitive Conditions and Quality of Primary Care. <i>Medical Care</i> , 2011, 49, 17-23.	1.1	58
88	Liposomal cytarabine is effective and tolerable in the treatment of central nervous system relapse of acute lymphoblastic leukemia and very aggressive lymphoma. <i>Haematologica</i> , 2011, 96, 238-244.	1.7	57
89	Status of minimal residual disease determines outcome of autologous hematopoietic SCT in adult ALL. <i>Bone Marrow Transplantation</i> , 2010, 45, 1095-1101.	1.3	56
90	The glutathione precursor N-acetylcysteine improves immune function in postmenopausal women. <i>Free Radical Biology and Medicine</i> , 2008, 45, 1252-1262.	1.3	55

#	ARTICLE	IF	CITATIONS
91	Characterizing Types of Human Mobility to Inform Differential and Targeted Malaria Elimination Strategies in Northeast Cambodia. <i>Scientific Reports</i> , 2015, 5, 16837.	1.6	54
92	Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance. <i>Blood</i> , 2011, 118, 4547-4553.	0.6	53
93	Pretreatment characteristics and clinical outcome of acute promyelocytic leukaemia patients according to the PML-RAR1± isoforms: a study of the PETHEMA group. <i>British Journal of Haematology</i> , 2001, 114, 99-103.	1.2	52
94	The Straw That Breaks the Camel's Back Redirecting Health-Seeking Behavior Studies on Malaria and Vulnerability. <i>Medical Anthropology Quarterly</i> , 2011, 25, 103-121.	0.7	52
95	Geographic variations in avoidable hospitalizations in the elderly, in a health system with universal coverage. <i>BMC Health Services Research</i> , 2008, 8, 42.	0.9	51
96	Aortic valve replacement in octogenarians. <i>Journal of Cardiothoracic Surgery</i> , 2007, 2, 33.	0.4	50
97	Predictive factors for poor peripheral blood stem cell mobilization and peak CD34+cell count to guide pre-emptive or immediate rescue mobilization.. <i>Cytotherapy</i> , 2012, 14, 823-829.	0.3	50
98	Social Determinants of Long Lasting Insecticidal Hammock-Use Among the Ra-Glai Ethnic Minority in Vietnam: Implications for Forest Malaria Control. <i>PLoS ONE</i> , 2012, 7, e29991.	1.1	50
99	Increased conventional chemotherapy does not improve survival in multiple myeloma: long-term results of two PETHEMA trials including 914 patients. <i>The Hematology Journal</i> , 2001, 2, 272-278.	2.0	50
100	Clinical significance of occult cerebrospinal fluid involvement assessed by flow cytometry in non-Hodgkin's lymphoma patients at high risk of central nervous system disease in the rituximab era. <i>European Journal of Haematology</i> , 2010, 85, 321-328.	1.1	49
101	Blinatumomab for Acute Lymphoblastic Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1498-1504.	2.0	49
102	Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia. <i>Cancer</i> , 2020, 126, 304-310.	2.0	49
103	Comparison of Intensive Chemotherapy, Allogeneic, or Autologous Stem-Cell Transplantation As Postremission Treatment for Children With Very High Risk Acute Lymphoblastic Leukemia: PETHEMA ALL-93 Trial. <i>Journal of Clinical Oncology</i> , 2007, 26, 16-24.	0.8	48
104	El anciano con cardiopatía terminal. <i>Revista Espanola De Cardiologia</i> , 2009, 62, 409-421.	0.6	48
105	Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia. <i>Hematology</i> , 2019, 24, 337-348.	0.7	48
106	Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome-negative adult lymphoblastic leukemia. <i>Blood</i> , 2021, 137, 1879-1894.	0.6	48
107	CTLA-4 genotype and relapse incidence in patients with acute myeloid leukemia in first complete remission after induction chemotherapy. <i>Leukemia</i> , 2009, 23, 486-491.	3.3	47
108	Prognostic indexes in follicular lymphoma: a comparison of different prognostic systems. <i>Annals of Oncology</i> , 2005, 16, 1508-1513.	0.6	46

#	ARTICLE	IF	CITATIONS
109	What Role Do Traditional Beliefs Play in Treatment Seeking and Delay for Buruli Ulcer Disease?â€“Insights from a Mixed Methods Study in Cameroon. PLoS ONE, 2012, 7, e36954.	1.1	45
110	High Mobility and Low Use of Malaria Preventive Measures Among the Jarai Male Youth Along the Cambodiaâ€“Vietnam Border. American Journal of Tropical Medicine and Hygiene, 2015, 93, 810-818.	0.6	45
111	Saccharomyces cerevisiae septicemia in septicemia in a patient with myelodysplastic syndrome. American Journal of Hematology, 1993, 43, 325-326.	2.0	43
112	Adverse prognostic impact of CD36 and CD2 expression in adult de novo acute myeloid leukemia patients. Leukemia Research, 2005, 29, 1109-1116.	0.4	43
113	Treatment of young patients with Philadelphia chromosomeâ€“positive acute lymphoblastic leukaemia using increased dose of imatinib and deintensified chemotherapy before allogeneic stem cell transplantation. British Journal of Haematology, 2012, 159, 78-81.	1.2	43
114	Prognostic significance of copy number alterations in adolescent and adult patients with precursor B acute lymphoblastic leukemia enrolled in PETHEMA protocols. Cancer, 2015, 121, 3809-3817.	2.0	43
115	Defining micro-epidemiology for malaria elimination: systematic review and meta-analysis. Malaria Journal, 2017, 16, 164.	0.8	43
116	CYP2D6, NAT2 and CYP2E1 genetic polymorphisms in nonagenarians. Age and Ageing, 1997, 26, 147-151.	0.7	42
117	Metalloproteinaseâ€™s Activity and Oxidative Stress in Mild Cognitive Impairment and Alzheimerâ€™s Disease. Neurochemical Research, 2009, 34, 373-378.	1.6	42
118	Prognostic factors in patients with HIVâ€“associated peripheral Tâ€“cell lymphoma: A multicenter study. American Journal of Hematology, 2011, 86, 256-261.	2.0	42
119	A new prognostic score for AIDS-related lymphomas in the rituximab-era. Haematologica, 2014, 99, 1731-1737.	1.7	42
120	Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia. Leukemia, 2012, 26, 1517-1526.	3.3	41
121	Adverse impact of IDH1 and IDH2 mutations in primary AML: Experience of the Spanish CETLAM group. Leukemia Research, 2012, 36, 990-997.	0.4	41
122	Core binding factor acute myeloid leukemia: the impact of age, leukocyte count, molecular findings, and minimal residual disease. European Journal of Haematology, 2013, 91, 209-218.	1.1	41
123	Feasibility and results of subtype-oriented protocols in older adults and fit elderly patients with acute lymphoblastic leukemia: Results of three prospective parallel trials from the PETHEMA group. Leukemia Research, 2016, 41, 12-20.	0.4	41
124	Injections, Cocktails and Diviners: Therapeutic Flexibility in the Context of Malaria Elimination and Drug Resistance in Northeast Cambodia. PLoS ONE, 2013, 8, e80343.	1.1	40
125	Genome-Wide DNA Copy Number Analysis of Acute Lymphoblastic Leukemia Identifies New Genetic Markers Associated with Clinical Outcome. PLoS ONE, 2016, 11, e0148972.	1.1	40
126	A multivariate analysis of prognostic factors in chronic myelomonocytic leukaemia according to the FAB criteria. British Journal of Haematology, 1987, 65, 307-311.	1.2	40



#	ARTICLE	IF	CITATIONS
127	Early lymphocyte activation in elderly humans: impaired T and T-dependent B cell responses. <i>Experimental Gerontology</i> , 1999, 34, 217-229.	1.2	38
128	Is mobilized peripheral blood comparable with bone marrow as a source of hematopoietic stem cells for allogeneic transplantation from HLA-identical sibling donors? A case-control study. <i>Haematologica</i> , 2009, 94, 1282-1288.	1.7	38
129	Immunophenotype of acute myeloid leukemia with NPM mutations: Prognostic impact of the leukemic compartment size. <i>Leukemia Research</i> , 2011, 35, 163-168.	0.4	38
130	Malaria in Pregnancy: What Can the Social Sciences Contribute?. <i>PLoS Medicine</i> , 2007, 4, e92.	3.9	37
131	HIV-infection impact on clinical biological features and outcome of diffuse large B-cell lymphoma treated with R-CHOP in the combination antiretroviral therapy era. <i>Aids</i> , 2015, 29, 811-818.	1.0	37
132	Profile of blinatumomab and its potential in the treatment of relapsed/refractory acute lymphoblastic leukemia. <i>OncoTargets and Therapy</i> , 2015, 8, 1567.	1.0	37
133	Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial. <i>Haematologica</i> , 2002, 87, 154-66.	1.7	37
134	Nilotinib (Tasigna®) and Low Intensity Chemotherapy for First-Line Treatment of Elderly Patients with BCR-ABL1-Positive Acute Lymphoblastic Leukemia: Final Results of a Prospective Multicenter Trial (EWALL-PH02). <i>Blood</i> , 2018, 132, 31-31.	0.6	36
135	Unrelated Transplantation for Poor-Prognosis Adult Acute Lymphoblastic Leukemia: Long-Term Outcome Analysis and Study of the Impact of Hematopoietic Graft Source. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 957-966.	2.0	35
136	Unrelated cord blood transplantation for adult patients with acute myeloid leukemia: higher incidence of acute graft-versus-host disease and lower survival in male patients transplanted with female unrelated cord blood—a report from Eurocord, the Acute Leukemia Working Party, and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the European Group for Blood and Marrow Transplantation. <i>Journal of Hematology and Oncology</i> , 2015, 8, 107.	6.9	35
137	Negative Blood Culture Infective Endocarditis in the Elderly: Long-Term Follow-Up. <i>Gerontology</i> , 2007, 53, 245-249.	1.4	34
138	A Word of Caution against the Stigma Trend in Neglected Tropical Disease Research and Control. <i>PLoS Neglected Tropical Diseases</i> , 2009, 3, e445.	1.3	34
139	Dose-intensive chemotherapy including rituximab is highly effective but toxic in human immunodeficiency virus-infected patients with Burkitt lymphoma/leukemia: parallel study of 81 patients. <i>Leukemia and Lymphoma</i> , 2014, 55, 2341-2348.	0.6	34
140	Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: A multi-institutional retrospective study. <i>Cancer</i> , 2015, 121, 423-431.	2.0	34
141	Mutations in TP53 and JAK2 are independent prognostic biomarkers in B-cell precursor acute lymphoblastic leukaemia. <i>British Journal of Cancer</i> , 2017, 117, 256-265.	2.9	34
142	Oral solid form of primary effusion lymphoma mimicking plasmablastic lymphoma. <i>Human Pathology</i> , 2004, 35, 632-635.	1.1	33
143	Monosomy 7 with severe myelodysplasia developing during imatinib treatment of Philadelphia-positive chronic myeloid leukemia: Two cases with a different outcome. <i>American Journal of Hematology</i> , 2007, 82, 849-851.	2.0	33
144	Efficacy and safety of bispecific T-cell engager blinatumomab and the potential to improve leukemia-free survival in B-cell acute lymphoblastic leukemia. <i>Expert Review of Hematology</i> , 2017, 10, 1057-1067.	1.0	33

#	ARTICLE	IF	CITATIONS
145	Ki-1+ anaplastic large-cell lymphoma of T-cell origin in an HIV-infected patient. <i>Aids</i> , 1991, 5, 751-756.	1.0	32
146	Optimal approach to treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: how to best use all the available tools. <i>Leukemia and Lymphoma</i> , 2013, 54, 21-27.	0.6	32
147	Outcome of graft failure after allogeneic stem cell transplant: study of 89 patients. <i>Leukemia and Lymphoma</i> , 2015, 56, 656-662.	0.6	32
148	Prognostic impact of highly active antiretroviral therapy in HIV-related Hodgkin's disease. <i>Aids</i> , 2002, 16, 1973-1976.	1.0	32
149	Lack of influence of human immunodeficiency virus infection status in the response to therapy and survival of adult patients with mature B-cell lymphoma or leukemia. Results of the PETHEMA-LAL3/97 study. <i>Haematologica</i> , 2003, 88, 445-53.	1.7	32
150	The prognosis of HIV-infected patients with diffuse large B-cell lymphoma treated with chemotherapy and highly active antiretroviral therapy is similar to that of HIV-negative patients receiving chemotherapy. <i>Haematologica</i> , 2005, 90, 704-6.	1.7	32
151	Feasibility and results of bone marrow transplantation after remission induction and intensification chemotherapy in de novo acute myeloid leukemia. Catalan Group for Bone Marrow Transplantation.. <i>Journal of Clinical Oncology</i> , 1996, 14, 1353-1363.	0.8	31
152	All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies. <i>Annals of Hematology</i> , 2015, 94, 1347-1356.	0.8	31
153	Increased serum tumour necrosis factor during transient remission in acute leukaemia. <i>Lancet, The</i> , 1993, 341, 1600.	6.3	30
154	Contribution of cerebrospinal fluid sCD19 levels to the detection of CNS lymphoma and its impact on disease outcome. <i>Blood</i> , 2014, 123, 1864-1869.	0.6	30
155	Clofarabine-based chemotherapy for relapsed/refractory adult acute lymphoblastic leukemia and lymphoblastic lymphoma. The Spanish experience. <i>American Journal of Hematology</i> , 2012, 87, 631-634.	2.0	29
156	<scp>MYC</scp> protein expression is associated with poor prognosis in primary diffuse large Bâ€cell lymphoma of the central nervous system. <i>Apmsis</i> , 2015, 123, 596-603.	0.9	29
157	Risk of sinusoidal obstruction syndrome in allogeneic stem cell transplantation after prior gemtuzumab ozogamicin treatment: a retrospective study from the Acute Leukemia Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2017, 52, 592-599.	1.3	29
158	Unique clinico-biological, genetic and prognostic features of adult early T-cell precursor acute lymphoblastic leukemia. <i>Haematologica</i> , 2020, 105, e294-e297.	1.7	29
159	Impact of minimal residual disease on outcomes after umbilical cord blood transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia: an analysis on behalf of Eurocord, Cord Blood Committee and the Acute Leukaemia working party of. <i>British Journal of Haematology</i> , 2014, 166, 749-757.	1.2	28
160	Stem cell mobilization in HIV seropositive patients with lymphoma. <i>Haematologica</i> , 2013, 98, 1762-1768.	1.7	27
161	Decrease in the frequency of meningeal involvement in AIDS-related systemic lymphoma in patients receiving HAART. <i>Haematologica</i> , 2008, 93, 149-150.	1.7	26
162	Targeted deep sequencing improves outcome stratification in chronic myelomonocytic leukemia with low risk cytogenetic features. <i>Oncotarget</i> , 2016, 7, 57021-57035.	0.8	26

#	ARTICLE	IF	CITATIONS
163	Centre characteristics and procedure-related factors have an impact on outcomes of allogeneic transplantation for patients with <sc>CLL</sc>: a retrospective analysis from the European Society for Blood and Marrow Transplantation (<sc>EBMT</sc>). <i>British Journal of Haematology</i> , 2017, 178, 521-533.	1.2	26
164	Acute Promyelocytic Leukemia in a HIV Seropositive Patient. <i>Leukemia and Lymphoma</i> , 1997, 26, 621-624.	0.6	25
165	Acute myeloblastic leukemia with minimal myeloid differentiation: phenotypical and ultrastructural characteristics. <i>Leukemia</i> , 1998, 12, 1071-1075.	3.3	25
166	In vivo quantification of response to treatment in patients with multiple myeloma by 1H magnetic resonance spectroscopy of bone marrow. <i>Magnetic Resonance Materials in Physics, Biology, and Medicine</i> , 2007, 20, 93-101.	1.1	25
167	Bottlenecks for High Coverage of Intermittent Preventive Treatment in Pregnancy: The Case of Adolescent Pregnancies in Rural Burkina Faso. <i>PLoS ONE</i> , 2010, 5, e12013.	1.1	25
168	Traditional Nets Interfere with the Uptake of Long-Lasting Insecticidal Nets in the Peruvian Amazon: The Relevance of Net Preference for Achieving High Coverage and Use. <i>PLoS ONE</i> , 2013, 8, e50294.	1.1	25
169	Highly active antiretroviral therapy and outcome of AIDS-related Burkitt's lymphoma or leukemia. Results of the PETHEMA-LAL3/97 study. <i>Haematologica</i> , 2005, 90, 990-2.	1.7	25
170	High clinical and molecular response rates with fludarabine, cyclophosphamide and mitoxantrone in previously untreated patients with advanced stage follicular lymphoma. <i>Haematologica</i> , 2008, 93, 207-214.	1.7	24
171	A scoring system to predict the risk of death during induction with anthracycline plus cytarabine-based chemotherapy in patients with de novo acute myeloid leukemia. <i>Cancer</i> , 2012, 118, 410-417.	2.0	24
172	Prognostic significance of complex karyotype and monosomal karyotype in adult patients with acute lymphoblastic leukemia treated with risk-adapted protocols. <i>Cancer</i> , 2014, 120, 3958-3964.	2.0	24
173	Long-term outcome of older patients with newly diagnosed de novo acute promyelocytic leukemia treated with ATRA plus anthracycline-based therapy. <i>Leukemia</i> , 2018, 32, 21-29.	3.3	24
174	Feasibility and results of autologous stem cell transplantation in de novo acute myeloid leukemia in patients over 60 years old. Results of the CETLAM AML-99 protocol. <i>Haematologica</i> , 2004, 89, 791-800.	1.7	24
175	Post-transplant Burkitt's Leukemia or Lymphoma. Study of Five Cases Treated with Specific Intensive Therapy (PETHEMA ALL-3/97 Trial). <i>Leukemia and Lymphoma</i> , 2003, 44, 1541-1543.	0.6	23
176	Usefulness and safety of oral cryotherapy in the prevention of oral mucositis after conditioning regimens with high-dose melphalan for autologous stem cell transplantation for lymphoma and myeloma. <i>European Journal of Haematology</i> , 2014, 93, 487-491.	1.1	23
177	Risk factors for outcomes after unrelated cord blood transplantation for adults with acute lymphoblastic leukemia: a report on behalf of Eurocord and the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2014, 49, 887-894.	1.3	23
178	Treatment of early stage-B chronic lymphocytic leukemia with alpha-2b interferon after chlorambucil reduction of the tumoral mass. <i>Annals of Hematology</i> , 1991, 63, 15-19.	0.8	22
179	Postural stability in the elderly: Fallers versus non-fallers. <i>European Geriatric Medicine</i> , 2011, 2, 1-5.	1.2	22
180	Allogeneic stem cell transplantation for adult acute lymphoblastic leukemia: when and how. <i>Haematologica</i> , 2011, 96, 1083-1086.	1.7	22

#	ARTICLE	IF	CITATIONS
181	Processing of the Platelet Amyloid Precursor Protein in the Mild Cognitive Impairment (MCI). <i>Neurochemical Research</i> , 2013, 38, 1415-1423.	1.6	22
182	Correlation of CD11b and CD56 expression in adult acute myeloid leukemia with cytogenetic risk groups and prognosis. <i>Annals of Hematology</i> , 2014, 93, 1483-1489.	0.8	22
183	Detection of Epstein-Barr Virus in Posttransplantation T Cell Lymphoma in a Kidney Transplant Recipient: Case Report and Review. <i>Clinical Infectious Diseases</i> , 2000, 30, 576-578.	2.9	21
184	Anorectal lymphoma without effusion associated with human herpesvirus-8 and type 1 epstein-barr virus in an hiv-infected patient. <i>Human Pathology</i> , 2003, 34, 630.	1.1	21
185	Translocation (3;8)(q27;q24) in two cases of triple hit lymphoma. <i>Cancer Genetics and Cytogenetics</i> , 2010, 203, 328-332.	1.0	21
186	TREATMENT OF ADOLESCENT AND YOUNG ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2014, 6, e2014052.	0.5	21
187	Clinical characteristics of patients with central nervous system relapse in BCR-ABL1-positive acute lymphoblastic leukemia: the importance of characterizing ABL1 mutations in cerebrospinal fluid. <i>Annals of Hematology</i> , 2017, 96, 1069-1075.	0.8	21
188	Copy number profiling of adult relapsed B-cell precursor acute lymphoblastic leukemia reveals potential leukemia progression mechanisms. <i>Genes Chromosomes and Cancer</i> , 2017, 56, 810-820.	1.5	21
189	Adherence to reporting guidelines increases the number of citations: the argument for including a methodologist in the editorial process and peer-review. <i>BMC Medical Research Methodology</i> , 2019, 19, 112.	1.4	21
190	Long-term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab. <i>Cancer</i> , 2021, 127, 554-559.	2.0	21
191	Ponatinib, chemotherapy, and transplant in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Blood Advances</i> , 2022, 6, 5395-5402.	2.5	21
192	Primary Myeloid Sarcoma of the Gynecologic Tract: A Report of Two Cases Progressing to Acute Myeloid Leukemia. <i>Leukemia and Lymphoma</i> , 2002, 43, 2151-2153.	0.6	20
193	Assessment of nephrotoxicity in patients receiving amphotericin B lipid complex: a pharmacosurveillance study in Spain. <i>Clinical Microbiology and Infection</i> , 2004, 10, 785-790.	2.8	20
194	Nonconvulsive status epilepticus associated with cefepime in a patient undergoing autologous stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2004, 33, 119-120.	1.3	20
195	Usefulness of tumor markers CA 125 and CA 15.3 at diagnosis and during follow-up in non-Hodgkin's lymphoma: study of 200 patients. <i>Leukemia and Lymphoma</i> , 2005, 46, 1471-1476.	0.6	20
196	Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trial. <i>Haematologica</i> , 2015, 100, 1207-1213.	1.7	20
197	The presence of genomic imbalances is associated with poor outcome in patients with burkitt lymphoma treated with dose-intensive chemotherapy including rituximab. <i>British Journal of Haematology</i> , 2016, 172, 428-438.	1.2	20
198	Refractoriness to immunochemotherapy in follicular lymphoma: Predictive factors and outcome. <i>Hematological Oncology</i> , 2017, 35, 520-527.	0.8	20

#	ARTICLE	IF	CITATIONS
199	Biomarkers associated with blinatumomab outcomes in acute lymphoblastic leukemia. <i>Leukemia</i> , 2021, 35, 2220-2231.	3.3	20
200	CD34+CD19 <sup>hi</sup> CD22+ B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies. <i>Blood</i> , 2022, 140, 38-44.	0.6	20
201	Favorable Impact of Virological Response to Highly Active Antiretroviral Therapy on Survival in Patients with AIDS-related Lymphoma. <i>Leukemia and Lymphoma</i> , 2002, 43, 1837-1842.	0.6	19
202	Successful response to rituximab in a patient with pure red cell aplasia complicating chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2002, 118, 1192-1192.	1.2	19
203	The expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2015, 5, e352-e352.	2.8	19
204	Central nervous system involvement in AIDS-related lymphomas. <i>British Journal of Haematology</i> , 2016, 173, 857-866.	1.2	19
205	Frequency and clinical impact of CDKN2A/ARF/CDKN2B gene deletions as assessed by in-depth genetic analyses in adult T cell acute lymphoblastic leukemia. <i>Journal of Hematology and Oncology</i> , 2018, 11, 96.	6.9	19
206	Cost-Effectiveness Analysis of Tisagenlecleucel in the Treatment of Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia in Children and Young Adults in Spain. <i>ClinicoEconomics and Outcomes Research</i> , 2020, Volume 12, 253-264.	0.7	19
207	Prevalence of human T-cell lymphotropic virus type 1 (HTLV-1) and HTLV-2 infection among Spanish drug users measured by HTLV-1 assay and HTLV-1 and -2 assay. HTLV-1 and HTLV-2 Spanish Study Group. <i>Journal of Clinical Microbiology</i> , 1995, 33, 1735-1738.	1.8	19
208	Compassionate use of intrathecal depot liposomal cytarabine as treatment of central nervous system involvement in acute leukemia: report of 6 cases. <i>Haematologica</i> , 2006, 91, ECR02.	1.7	19
209	Initial results and long-term clinical and angiographic implications of coronary stenting in elderly patients. <i>American Journal of Cardiology</i> , 1999, 83, 1483-1487.	0.7	18
210	Human immunodeficiency virus-related non-Hodgkin's lymphoma. <i>Haematologica</i> , 2008, 93, 1129-1132.	1.7	18
211	Isochromosome 17q as a sole anomaly: A distinct myelodysplastic syndrome entity?. <i>Leukemia Research</i> , 1993, 17, 717-720.	0.4	17
212	Improved Outcome of AIDS-Related Lymphoma in Patients With Virologic Response to Highly Active Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003, 32, 347-348.	0.9	17
213	Advances in acute lymphoblastic leukemia in adults. <i>Current Opinion in Oncology</i> , 2011, 23, 692-699.	1.1	17
214	Frequency and prognostic significance of additional cytogenetic abnormalities to the Philadelphia chromosome in young and older adults with acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 146-154.	0.6	17
215	Blinatumomab vs historic standard of care treatment for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukaemia. <i>European Journal of Haematology</i> , 2020, 104, 299-309.	1.1	17
216	The Yin and Yang-Like Clinical Implications of the CDKN2A/ARF/CDKN2B Gene Cluster in Acute Lymphoblastic Leukemia. <i>Genes</i> , 2021, 12, 79.	1.0	17

#	ARTICLE	IF	CITATIONS
217	Frequency, Clinical Characteristics and Outcome of Adults With Acute Lymphoblastic Leukemia and COVID 19 Infection in the First vs. Second Pandemic Wave in Spain. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e801-e809.	0.2	17
218	Clinical Prognostic Factors in Chemosensitive Multiple Myeloma (MM) Patients Intensified with High Dose Therapy/Stem Cell Support (HDT/SCS): Results of the Spanish Trial (PETHEMA/GEM2000).. <i>Blood</i> , 2007, 110, 937-937.	0.6	17
219	Electron Microscopic Identification of Parvovirus Virions in Erythroid and Granulocytic-Line Cells in a Patient with Human Parvovirus B19 Induced Pancytopenia. <i>Leukemia and Lymphoma</i> , 1993, 10, 483-487.	0.6	16
220	Early T Cell Activation in Elderly Humans. <i>Age and Ageing</i> , 1996, 25, 470-478.	0.7	16
221	Second Mobilization and Collection of Peripheral Blood Progenitor Cells in Healthy Donors Is Associated with Lower CD34+Cell Yields. <i>Journal of Hematotherapy and Stem Cell Research</i> , 2002, 11, 705-709.	1.8	16
222	Prospective Study of Fecal Colonization by Extended-Spectrum-β-Lactamase-Producing <i>Escherichia coli</i> in Neutropenic Patients with Cancer. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 4187-4190.	1.4	16
223	Immunohistochemical expression profile and prognosis in patients with diffuse large B-cell lymphoma with or without human immunodeficiency virus infection. <i>Leukemia and Lymphoma</i> , 2010, 51, 2063-2069.	0.6	16
224	Umbilical cord blood transplantation from unrelated donors in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Haematologica</i> , 2014, 99, 378-384.	1.7	16
225	Results of treatment with azacitidine in patients aged ≥ 75 years included in the Spanish Registry of Myelodysplastic Syndromes. <i>Leukemia and Lymphoma</i> , 2014, 55, 1300-1303.	0.6	16
226	Epigenetic loss of the RNA decapping enzyme NUDT16 mediates C-MYC activation in T-cell acute lymphoblastic leukemia. <i>Leukemia</i> , 2017, 31, 1622-1625.	3.3	16
227	The European LeukemiaNet: achievements and perspectives. <i>Haematologica</i> , 2011, 96, 156-162.	1.7	15
228	Lack of negative impact of Philadelphia chromosome in older patients with acute lymphoblastic leukaemia in the tyrosine kinase inhibitor era: comparison of two prospective parallel protocols. <i>British Journal of Haematology</i> , 2012, 159, 485-488.	1.2	15
229	Hematopoietic Stem Cell Transplantation in Patients with Lymphomatoid Granulomatosis: A European Group for Blood and Marrow Transplantation Report. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1522-1525.	2.0	15
230	Long-term follow up of patients with human immunodeficiency virus infection and advanced stage Hodgkin's lymphoma treated with doxorubicin, bleomycin, vinblastine and dacarbazine. <i>Haematologica</i> , 2013, 98, e85-e86.	1.7	15
231	The long term follow-up of early stage follicular lymphoma treated with radiotherapy, chemotherapy or combined modality treatment. <i>Leukemia Research</i> , 2015, 39, 853-858.	0.4	15
232	First European Chemotherapy Schedule for Elderly Patients with Acute Lymphoblastic Leukemia: Promising Remission Rate and Feasible Moderate Dose Intensity Consolidation. <i>Blood</i> , 2008, 112, 304-304.	0.6	15
233	Clinicobiological features, treatment and survival of 457 patients with histological Grades 3A and 2 follicular lymphoma mostly treated with immunochemotherapy. <i>British Journal of Haematology</i> , 2016, 172, 470-473.	1.2	14
234	Incidence, clinical and biological characteristics and outcome of secondary acute lymphoblastic leukemia after solid organ or hematologic malignancy. <i>Leukemia and Lymphoma</i> , 2016, 57, 86-91.	0.6	14

#	ARTICLE	IF	CITATIONS
235	HIV-infection has no prognostic impact on advanced-stage Hodgkin lymphoma. <i>Aids</i> , 2017, 31, 1445-1449.	1.0	14
236	Reactive community-based self-administered treatment against residual malaria transmission: study protocol for a randomized controlled trial. <i>Trials</i> , 2018, 19, 126.	0.7	14
237	Community perspectives on treating asymptomatic infections for malaria elimination in The Gambia. <i>Malaria Journal</i> , 2019, 18, 39.	0.8	14
238	Increased survival due to lower toxicity for high-risk T-cell acute lymphoblastic leukemia patients in two consecutive pediatric-inspired PETHEMA trials. <i>European Journal of Haematology</i> , 2019, 102, 79-86.	1.1	14
239	A Phase I/II National, Multi-Center, Open-Label Study of Bortezomib Plus Melphalan and Prednisone (V-MP) in Elderly Untreated Multiple Myeloma Patients.. <i>Blood</i> , 2004, 104, 3462-3462.	0.6	14
240	Probability of the Development of Non-Hodgkin's Lymphoma in Primary Sjögren's Syndrome. <i>Scandinavian Journal of Rheumatology</i> , 1996, 25, 396-397.	0.6	13
241	Mobilization and engraftment of peripheral blood stem cells in healthy related donors >55 years old. <i>Cytotherapy</i> , 2014, 16, 406-411.	0.3	13
242	Complex Measurements May Be Required to Establish the Prognostic Impact of Immunophenotypic Markers in AML. <i>American Journal of Clinical Pathology</i> , 2015, 144, 484-492.	0.4	13
243	Therapy-related acute lymphoblastic leukemia. <i>Haematologica</i> , 2018, 103, 1581-1583.	1.7	13
244	Incidence and outcome after first molecular versus overt recurrence in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia included in the ALL Ph08 trial from the Spanish PETHEMA Group. <i>Cancer</i> , 2019, 125, 2810-2817.	2.0	13
245	Response to Novel Drugs before and after Allogeneic Stem Cell Transplantation in Patients with Relapsed Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1703-1712.	2.0	13
246	The evolution of relapse of adult T cell acute lymphoblastic leukemia. <i>Genome Biology</i> , 2020, 21, 284.	3.8	13
247	A pediatric regimen for adolescents and young adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: Results of the ALLRE08 PETHEMA trial. <i>Cancer Medicine</i> , 2020, 9, 2317-2329.	1.3	13
248	Hodgkin Lymphoma in People Living with HIV. <i>Cancers</i> , 2021, 13, 4366.	1.7	13
249	Efficacy and safety of native versus pegylated <i>Escherichia coli</i> asparaginase for treatment of adults with high-risk, Philadelphia chromosome-negative acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 1634-1643.	0.6	13
250	Dasatinib (Sprycel®) and Low Intensity Chemotherapy for First-Line Treatment in Patients with De Novo Philadelphia Positive ALL Aged 55 and Over: Final Results of the EWALL-Ph-01 Study. <i>Blood</i> , 2012, 120, 666-666.	0.6	13
251	Alpha interferon in chronic lymphocytic leukaemia. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1991, 27, S74-S77.	0.9	12
252	Low-Grade, Malt-type, Primary B-Cell Lymphoma of the Conjunctiva. <i>Leukemia and Lymphoma</i> , 1997, 28, 203-207.	0.6	12

#	ARTICLE	IF	CITATIONS
253	Essential monoclonal gammopathy with an IgM paraprotein that is a cryoglobulin with cold agglutinin and EDTA-dependent platelet antibody properties. <i>British Journal of Haematology</i> , 1998, 100, 603-604.	1.2	12
254	H-RAS 1 Minisatellite Rare Alleles: A Genetic Susceptibility and Prognostic Factor for Non-Hodgkin's Lymphoma. <i>Journal of the National Cancer Institute</i> , 1998, 90, 1095-1098.	3.0	12
255	Acute promyelocytic leukemia in a patient with idiopathic myelofibrosis. <i>Leukemia</i> , 1999, 13, 492-494.	3.3	12
256	Immune hemolytic anemia induced by 6-mercaptopurine. <i>Transfusion</i> , 2000, 40, 75-76.	0.8	12
257	Results of Compassionate Therapy with Intrathecal Depot Liposomal Cytarabine in Acute Myeloid Leukemia Meningeosis. <i>International Journal of Hematology</i> , 2007, 86, 33-36.	0.7	12
258	Long-term follow-up of patients with HIV-related diffuse large B-cell lymphomas treated in a phase II study with rituximab and CHOP. <i>British Journal of Haematology</i> , 2012, 157, 637-639.	1.2	12
259	Usefulness of IGH/TCR PCR studies in lymphoproliferative disorders with inconclusive clonality by flow cytometry. , 2014, 86, 25-31.		12
260	Re-imagining adherence to treatment from the other side: local interpretations of adverse anti-malarial drug reactions in the Peruvian Amazon. <i>Malaria Journal</i> , 2016, 15, 136.	0.8	12
261	Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA and chemotherapy. <i>Leukemia and Lymphoma</i> , 2019, 60, 1146-1155.	0.6	12
262	Impact of detectable measurable residual disease on umbilical cord blood transplantation. <i>American Journal of Hematology</i> , 2020, 95, 1057-1065.	2.0	12
263	Acute myeloid leukemia with inv(3)(q21.3q26.2)/t(3;3)(q21.3;q26.2): Study of 61 patients treated with intensive protocols. <i>European Journal of Haematology</i> , 2020, 105, 138-147.	1.1	12
264	Confirmatory open-label, single-arm, multicenter phase 2 study of the BiTE antibody blinatumomab in patients (pts) with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL).. <i>Journal of Clinical Oncology</i> , 2014, 32, 7005-7005.	0.8	12
265	Systemic candidiasis in drug addicts. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1985, 4, 509-512.	1.3	11
266	Isochromosome 14q in chronic myelomonocytic leukemia. <i>Cancer Genetics and Cytogenetics</i> , 1991, 52, 139-140.	1.0	11
267	Prospective study on the practice of central nervous system prophylaxis and treatment in non-Hodgkin's lymphoma in Spain. <i>Medicina Clínica</i> , 2008, 131, 441-446.	0.3	11
268	Plasma Epstein-Barr Virus Load as an Early Biomarker and Prognostic Factor of Human Immunodeficiency Virus-related Lymphomas. <i>Clinical Infectious Diseases</i> , 2019, 68, 834-843.	2.9	11
269	Adverse prognostic impact of complex karyotype (≥3 cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL). <i>Leukemia Research</i> , 2021, 109, 106612.	0.4	11
270	Occlusion of the superior mesenteric artery in a patient with Polycythemia vera: Resolution with percutaneous transluminal angioplasty. <i>Annals of Hematology</i> , 1996, 72, 89-91.	0.8	10



#	ARTICLE	IF	CITATIONS
271	Epidemiology of HTLV-I Infection in Spain. <i>International Journal of Epidemiology</i> , 1996, 25, 443-449.	0.9	10
272	AA-type Amyloid Tumor as an Unsuspected Cause of Residual Mass in a Patient With Large B-cell Non-Hodgkin's Lymphoma. <i>Leukemia and Lymphoma</i> , 2002, 43, 681-682.	0.6	10
273	Plasma Epstein-Barr viral load measurement as a diagnostic marker of lymphoma in HIV-infected patients. <i>Medicina Clínica</i> , 2010, 135, 485-490.	0.3	10
274	Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors. <i>Medicina Clínica</i> , 2013, 141, 95-99.	0.3	10
275	EHA evaluation of the ESMO's Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies. <i>ESMO Open</i> , 2020, 5, e000611.	2.0	10
276	A novel targeted RNA-Seq panel identifies a subset of adult patients with acute lymphoblastic leukemia with BCR-ABL1-like characteristics. <i>Blood Cancer Journal</i> , 2020, 10, 43.	2.8	10
277	Specific Chemotherapy and Rituximab In HIV-Infected Patients with Burkitt's Leukemia or Lymphoma. Results of a German-Spanish Study and Analysis of Prognostic Factors. <i>Blood</i> , 2010, 116, 3944-3944.	0.6	10
278	Tumour Lysis Syndrome with Hypocalcaemia in Accelerated Chronic Granulocytic Leukaemia. <i>Acta Haematologica</i> , 1982, 68, 157-159.	0.7	9
279	Cutaneous Myeloid Metaplasia with Dysplastic Features in Idiopathic Myelofibrosis. <i>International Journal of Dermatology</i> , 1988, 27, 179-180.	0.5	9
280	Clinical outcome after sex-mismatched allogeneic stem cell transplantation from human lymphocyte antigen-identical sibling donors: influence of stem cell source. <i>Leukemia</i> , 2006, 20, 1461-1464.	3.3	9
281	Acute transformation of chronic myelomonocytic leukaemia: a multivariate study of predictive factors. <i>European Journal of Haematology</i> , 1989, 42, 284-288.	1.1	9
282	Plerixafor plus G-CSF in combination with chemotherapy for stem cell mobilization in a pediatric patient with Ewing's sarcoma. <i>Journal of Clinical Apheresis</i> , 2012, 27, 260-262.	0.7	9
283	Comparison of intensive, pediatric-inspired therapy with non-intensive therapy in older adults aged 55-65 years with Philadelphia chromosome-negative acute lymphoblastic leukemia. <i>Leukemia Research</i> , 2018, 68, 79-84.	0.4	9
284	Incidence, predictive factors, management, and survival impact of atrial fibrillation in non-Hodgkin lymphoma. <i>Annals of Hematology</i> , 2018, 97, 1633-1640.	0.8	9
285	An analysis of the impact of CD56 expression in <i>de novo</i> acute promyelocytic leukemia patients treated with upfront all-trans retinoic acid and anthracycline-based regimens. <i>Leukemia and Lymphoma</i> , 2019, 60, 1030-1035.	0.6	9
286	Post-Remission Treatment with Chemotherapy or Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) of High-Risk (HR) Philadelphia Chromosome-Negative (Ph-neg) Adult Acute Lymphoblastic Leukemia (ALL) According to Minimal Residual Disease (MRD). Preliminary Results of the Pethema ALL-HR-11 Trial. <i>Blood</i> , 2015, 126, 1333-1333.	0.6	9
287	Philadelphia chromosome-like acute lymphoblastic leukemia. Still a pending matter. <i>Haematologica</i> , 2021, 106, 1514-1516.	1.7	9
288	Functional integrity of the CD28 co-stimulatory pathway in T lymphocytes from elderly subjects. <i>Age and Ageing</i> , 1999, 28, 221-227.	0.7	8

#	ARTICLE	IF	CITATIONS
289	Advanced Stage Is the Most Important Prognostic Factor for Survival in Patients with Systemic Acquired Immunodeficiency Syndrome-Related Non-Hodgkin's Lymphoma Treated with CHOP and Highly Active Antiretroviral Therapy. <i>International Journal of Hematology</i> , 2007, 86, 337-342.	0.7	8
290	Comparison of CHOP treatment with specific short-intensive chemotherapy in AIDS-related Burkitt's lymphoma or leukemia. <i>Medicina Clínica</i> , 2011, 136, 323-328.	0.3	8
291	Acute lymphoblastic leukemia in adults. <i>Mental Illness</i> , 2011, 3, 1.	0.8	8
292	Lack of impact of human immunodeficiency virus infection on the outcome of lymphoma patients transferred to the intensive care unit. <i>Leukemia and Lymphoma</i> , 2012, 53, 1966-1970.	0.6	8
293	The role of idecabtagene vicleucel in patients with heavily pretreated refractory multiple myeloma. <i>Therapeutic Advances in Hematology</i> , 2021, 12, 204062072110196.	1.1	8
294	Outcomes After Double Unit Unrelated Cord Blood Transplantation (UCBT) Compared with Single UCBT In Adults with Acute Leukemia In Remission. An Eurocord and ALWP Collaboration Study. <i>Blood</i> , 2010, 116, 910-910.	0.6	8
295	Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients. <i>Leukemia and Lymphoma</i> , 2022, 63, 538-550.	0.6	8
296	Porphyria cutanea tarda and chronic myelomonocytic leukemia. <i>American Journal of Hematology</i> , 1989, 31, 299-299.	2.0	7
297	Effectiveness of Local Radiotherapy in Primary Extranodal Marginal Zone B-cell Lymphoma of MALT or MALT Lymphoma of Conjunctiva: Study of Four Cases. <i>Leukemia and Lymphoma</i> , 2002, 43, 1975-1977.	0.6	7
298	Limited prognostic value of the International Prognostic Score in advanced stage human immunodeficiency virus infection-related Hodgkin lymphoma treated with the doxorubicin, bleomycin, vinblastine, and dacarbazine regimen. <i>Leukemia and Lymphoma</i> , 2009, 50, 1718-1720.	0.6	7
299	Frequency and prognostic significance of t(v;11q23)/KMT2A rearrangements in adult patients with acute lymphoblastic leukemia treated with risk-adapted protocols. <i>Leukemia and Lymphoma</i> , 2017, 58, 145-152.	0.6	7
300	Long-term safety and outcome of fludarabine, cyclophosphamide and mitoxantrone (FCM) regimen in previously untreated patients with advanced follicular lymphoma: 12Âyears follow-up of a phase 2 trial. <i>Annals of Hematology</i> , 2017, 96, 639-646.	0.8	7
301	Association of aplastic anaemia and lymphoma: a report from the severe aplastic anaemia working party of the European Society of Blood and Bone Marrow Transplantation. <i>British Journal of Haematology</i> , 2019, 184, 294-298.	1.2	7
302	Comparison of Efficacy and Safety Results in 103 Treatment-NaÃve Acute Myeloid Leukemia (TN-AML) Patients Not Candidates for Intensive Chemotherapy Using 5-Day and 10-Day Regimens of Guadecitabine (SGI-110), a Novel Hypomethylating Agent (HMA). <i>Blood</i> , 2015, 126, 458-458.	0.6	7
303	Erythema nodosum as a presenting feature of T-cell-rich B-cell lymphoma. <i>Annals of Hematology</i> , 1995, 70, 107-108.	0.8	6
304	Feasibility and efficacy of outpatient therapy with intermediate dose cytarabine, fludarabine and idarubicin for patients with acute myeloid leukaemia aged 70 or older. <i>European Journal of Haematology</i> , 2015, 95, 576-582.	1.1	6
305	Highly variable mutational profile of <i><sc>ASXL</sc>1</i> in myelofibrosis. <i>European Journal of Haematology</i> , 2016, 97, 331-335.	1.1	6
306	Molecular profiling refines minimal residual diseaseâ€based prognostic assessment in adults with Philadelphia chromosomeâ€negative Bâ€cell precursor acute lymphoblastic leukemia. <i>Genes Chromosomes and Cancer</i> , 2019, 58, 815-819.	1.5	6

#	ARTICLE	IF	CITATIONS
307	The poor prognosis of low hypodiploidy in adults with B-cell precursor acute lymphoblastic leukaemia is restricted to older adults and elderly patients. <i>British Journal of Haematology</i> , 2019, 186, 263-268.	1.2	6
308	Using the Lymph2Cx assay for assessing cell-of-origin subtypes of HIV-related diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2019, 60, 1087-1091.	0.6	6
309	Characteristics and outcome of adult patients with acute promyelocytic leukemia and increased body mass index treated with the PETHEMA Protocols. <i>European Journal of Haematology</i> , 2020, 104, 162-169.	1.1	6
310	Integrated Genomic Analysis of Chromosomal Alterations and Mutations in B-Cell Acute Lymphoblastic Leukemia Reveals Distinct Genetic Profiles at Relapse. <i>Diagnostics</i> , 2020, 10, 455.	1.3	6
311	Post-transplant Burkitt's Leukemia or Lymphoma. Study of Five Cases Treated with Specific Intensive Therapy (PETHEMA ALL-3/97 Trial). <i>Leukemia and Lymphoma</i> , 2003, 44, 1541-1543.	0.6	6
312	Final Results of a Phase II Trial with Plitidepsin (Aplidin) Alone and in Combination with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2008, 112, 3700-3700.	0.6	6
313	Characteristics and Outcome of Early T Cell Precursor ALL (ETP-ALL) Patients Treated with High-Risk Spanish Pethema Protocols. <i>Blood</i> , 2018, 132, 1553-1553.	0.6	6
314	Characteristics of red cell pyruvate kinase (PK) and pyrimidine 5'nucleotidase (P5N) abnormalities in acute leukaemia and chronic lymphoid diseases with leukaemic expression. <i>British Journal of Haematology</i> , 1987, 66, 173-177.	1.2	5
315	Transient demyelinating neurologic lesions in a patient with idiopathic hypereosinophilic syndrome. <i>American Journal of Hematology</i> , 2002, 69, 153-154.	2.0	5
316	Response to highly active antiretroviral therapy as the only therapy in an HIV-infected patient with interfollicular Hodgkin's lymphoma. <i>Leukemia and Lymphoma</i> , 2007, 48, 2058-2059.	0.6	5
317	Antithymocyte globulin therapy for steroid-resistant acute graft versus host disease. <i>American Journal of Hematology</i> , 2008, 83, 824-825.	2.0	5
318	Practice of central nervous system prophylaxis and treatment in acute leukemias in Spain. Prospective registry study. <i>Medicina Clínica</i> , 2008, 131, 401-405.	0.3	5
319	Shrinking and boundedly complete Schauder frames in Fréchet spaces. <i>Journal of Mathematical Analysis and Applications</i> , 2014, 410, 953-966.	0.5	5
320	Flow cytometry for detection of central nervous system disease in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2015, 56, 2190-2192.	0.6	5
321	Impact of transplant eligibility and availability of a human leukocyte antigen-identical matched related donor on outcome of older patients with acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2015, 56, 2812-2818.	0.6	5
322	Acute Gastroenteritis and Campylobacteriosis in Swiss Primary Care: The Viewpoint of General Practitioners. <i>PLoS ONE</i> , 2016, 11, e0161650.	1.1	5
323	The clinical dilemma of grade 3 follicular lymphoma. <i>Annals of Oncology</i> , 2016, 27, 1974.	0.6	5
324	Relapse risk after autologous stem cell transplantation in patients with lymphoma based on CD34+ cell dose. <i>Leukemia and Lymphoma</i> , 2017, 58, 916-922.	0.6	5

#	ARTICLE	IF	CITATIONS
325	Can the collection of expired long-lasting insecticidal nets reduce their coverage and use? Sociocultural aspects related to LLIN life cycle management and use in four districts in Madagascar. <i>Malaria Journal</i> , 2017, 16, 404.	0.8	5
326	Recomendaciones de GESIDA/PETHEMA sobre el diagnóstico y tratamiento de los linfomas en pacientes infectados por el virus de la inmunodeficiencia humana. <i>Medicina Clínica</i> , 2018, 151, 39.e1-39.e17.	0.3	5
327	Treatment of Frail Older Adults and Elderly Patients With Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia: Results of a Prospective Trial With Minimal Chemotherapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e513-e522.	0.2	5
328	Prognostic Factors and Long-Term Outcome for Patients with Hodgkin's Lymphoma Who Relapse after an Autologous Stem Cell Transplantation.. <i>Blood</i> , 2004, 104, 1649-1649.	0.6	5
329	Intensive Chemotherapy (High-Dose CHOP/ESHAP Regimen) Followed by Autologous Stem-Cell Transplantation (ASCT) in Previously Untreated Patients with Peripheral T-Cell Lymphoma (PTCL). Results of a Prospective Phase II Study from the GELCAB.. <i>Blood</i> , 2005, 106, 2077-2077.	0.6	5
330	Treatment of High-Risk (HR) Philadelphia Chromosome-Negative (Ph-) Adult Acute Lymphoblastic Leukemia (ALL) According to Baseline Risk Factors and Minimal Residual Disease (MRD). Results of the PETHEMA ALL-AR-03 Trial Including the Use of Propensity Score (PS) Method to Reduce Assignment Bias.. <i>Blood</i> , 2009, 114, 322-322.	0.6	5
331	Recent Spread of Human T Lymphotropic Virus Type II among Injecting Drug Users in Spain. <i>Journal of Infectious Diseases</i> , 1996, 174, 891-891.	1.9	4
332	A step forward in therapy for ALL in infants. <i>Lancet</i> , The, 2007, 370, 198-200.	6.3	4
333	Metabolic fingerprinting of fresh lymphoma samples used to discriminate between follicular and diffuse large B-cell lymphomas. <i>Experimental Hematology</i> , 2009, 37, 1259-1265.	0.2	4
334	Epstein-Barr viral loads and serum free light chains levels are potential follow-up markers of HIV-related lymphomas. <i>Leukemia and Lymphoma</i> , 2017, 58, 211-213.	0.6	4
335	Impact of induction treatment before autologous stem cell transplantation on long-term outcome in patients with newly diagnosed multiple myeloma. <i>European Journal of Haematology</i> , 2017, 98, 569-576.	1.1	4
336	Open questions in watchful waiting for follicular lymphoma. <i>British Journal of Haematology</i> , 2017, 179, 679-681.	1.2	4
337	Effects of electrical stimulation in the treatment of osteonecrosis of the femoral head. <i>HIP International</i> , 2018, 28, 434-441.	0.9	4
338	The role of stem cell transplantation in the management of Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Therapeutic Advances in Hematology</i> , 2018, 9, 357-368.	1.1	4
339	Refractoriness to rituximab-based therapy and elevated serum B2-microglobulin predict for inferior survival in marginal zone lymphoma. <i>Leukemia and Lymphoma</i> , 2019, 60, 2524-2531.	0.6	4
340	Bispecific T-cell engaging antibodies in B-cell precursor acute lymphoblastic leukemias: focus on blinatumomab. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072091963.	1.1	4
341	Increased serum levels of CD44s and CD44v6 in patients with AIDS-related non-Hodgkin's lymphoma. <i>Aids</i> , 2000, 14, 1460-1461.	1.0	4
342	Comparative Study of Autologous Stem Cell Transplant (ASCT) in HIV-1 Positive (HIV+) on Haart and HIV-1 Negative (HIV-) Non Hodgkin Lymphoma (NHL) Patients.. <i>Blood</i> , 2006, 108, 3063-3063.	0.6	4

#	ARTICLE	IF	CITATIONS
343	Clinical Outcome According to Both Cytogenetic Abnormalities (CA) Detected by Fluorescence In Situ Hybridization (FISH) and Hyperdiploidy Assessed by Flow Cytometry (FCM) In Elderly Newly Diagnosed Myeloma Patients Treated with A Bortezomib-Based Combination. <i>Blood</i> , 2010, 116, 309-309.	0.6	4
344	Hodgkin's Disease and HIV Infection (HD-HIV): Prognostic Factors In 596 Patients (pts) within the European Group for the Study of HIV and Tumours (GECAT). <i>Blood</i> , 2010, 116, 3883-3883.	0.6	4
345	Ponatinib and Chemotherapy in Adults with <i>De Novo</i> Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Final Results of Ponalfil Clinical Trial. <i>Blood</i> , 2021, 138, 1230-1230.	0.6	4
346	Myeloproliferative disease in two young siblings. <i>Cancer</i> , 1984, 54, 899-902.	2.0	3
347	Giant cell arteritis presenting as a supraclavicular nodule.. <i>Annals of the Rheumatic Diseases</i> , 1990, 49, 202-203.	0.5	3
348	Percutaneous Transluminal Coronary Angioplasty for Post-infarction Angina in Elderly Patients. <i>Age and Ageing</i> , 1993, 22, 31-36.	0.7	3
349	Promoci3n de la donaci3n de sangre en un hospital: comparaci3n de dos sistemas. <i>Medicina Cl3nica</i> , 2002, 118, 174-176.	0.3	3
350	Clinical usefulness of fluorescence in situ hybridization for detection of MLL rearrangements in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2015, 56, 2706-2708.	0.6	3
351	Central nervous system relapse in diffuse large B cell lymphoma: Risk factors. <i>Medicina Cl3nica (English Edition)</i> , 2016, 146, 74-80.	0.1	3
352	CD34 expression and the outcome of nucleophosmin 1-mutated acute myeloid leukemia. <i>Annals of Hematology</i> , 2016, 95, 1949-1954.	0.8	3
353	New drugs for follicular lymphoma. <i>Leukemia Research</i> , 2016, 49, 38-46.	0.4	3
354	Feasibility of the AML profiler (Skyline, Array) for patient risk stratification in a multicentre trial: a preliminary comparison with the conventional approach. <i>Hematological Oncology</i> , 2017, 35, 778-788.	0.8	3
355	Incidence and prognostic significance of nephrotoxicity in patients receiving eshap as salvage therapy for lymphoma. <i>Leukemia Research</i> , 2017, 58, 98-101.	0.4	3
356	Frames and representing systems in Fr3chet spaces and their duals. <i>Banach Journal of Mathematical Analysis</i> , 2017, 11, 1-20.	0.4	3
357	Genome-wide identification of microRNA signatures associated with stem/progenitor cells in Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Molecular Biology Reports</i> , 2019, 46, 1295-1306.	1.0	3
358	Long-term outcome comparing histological grades of follicular lymphoma patients treated with immunochemotherapy as first-line therapy: A retrospective analysis from two institutions. <i>European Journal of Haematology</i> , 2020, 104, 198-206.	1.1	3
359	Outcomes and prognostic factors of adults with refractory or relapsed T-cell acute lymphoblastic leukemia included in measurable residual disease-oriented trials. <i>Hematological Oncology</i> , 2021, 39, 529-538.	0.8	3
360	Comparison of Intensive Chemotherapy (CHT), Allogeneic (ALLO) or Autologous (AUTO) Stem Cell Transplantation (SCT) as Post-Remission Treatment for Children with Very High-Risk Acute Lymphoblastic Leukemia (VHR-ALL). Final Results of the PETHEMA ALL-93 Trial.. <i>Blood</i> , 2005, 106, 173-173.	0.6	3

#	ARTICLE	IF	CITATIONS
361	Autologous Stem Cell Transplantation (ASCT) in HIV Associated Lymphoma (HIV-Ly) Patients: The EBMT Lymphoma Working Party (EBMT-LWP) Experience.. Blood, 2006, 108, 3042-3042.	0.6	3
362	Prognostic Value of Monosomal Karyotype in Patients with Primary Acute Myeloid Leukemia On Behalf of Spanish CETLAM Group.. Blood, 2009, 114, 1003-1003.	0.6	3
363	Comparison of Efficacy and Safety of Two Types of E.coli Asparaginase (Native or Pegylated) for Treatment of Adult Patients with High-Risk (HR), Philadelphia (Ph) Chromosome-Negative ALL Included in the Prospective MRD-Oriented Protocol ALL-HR-11 from the Spanish Pethema Group. Blood, 2016, 128, 180-180.	0.6	3
364	Lexical encapsulation and evaluation in parliamentary debate. ELUA Estudios De Lingüística Universidad De Alicante, 2018, , 291.	0.0	3
365	Oral induction and consolidation chemotherapy with idarubicin and etoposide in elderly patients with acute myeloid leukemia. Haematologica, 2003, 88, 229-30.	1.7	3
366	Recombinant alpha 2-interferon in the treatment of B chronic lymphocytic leukemia in early stages. Blood, 1988, 71, 1295-1298.	0.6	3
367	Usefulness of Y-body study on bone marrow smears to demonstrate the origin of fibroblast stromal cells in allogeneic bone marrow transplantation. Blut, 1990, 61, 14-16.	1.2	2
368	Primary Hodgkin's Disease of the Tonsil. Report of a Case and Review of the Literature. Leukemia and Lymphoma, 1992, 6, 271-273.	0.6	2
369	Síndrome de linfocitosis CD8 infiltrativo difuso en un paciente con infección por el virus de la inmunodeficiencia humana. Medicina Clínica, 2000, 115, 399.	0.3	2
370	A case of non-lethal pulmonary air embolism after leukapheresis catheter removal. Journal of Clinical Apheresis, 2005, 20, 93-94.	0.7	2
371	Adverse prognosis of bulky disease in good-risk DLBCL. Lancet Oncology, The, 2008, 9, 406-407.	5.1	2
372	ON THE DIFFICULTIES IN THE DIAGNOSIS OF HAIRY CELL LEUKAEMIA. Scandinavian Journal of Haematology, 1984, 33, 492-493.	0.0	2
373	Hope for very elderly patients with diffuse large B-cell lymphoma. Lancet Oncology, The, 2011, 12, 412-413.	5.1	2
374	Protective factors in patients aged over 65 with stroke treated by physiotherapy, showing cognitive impairment, in the Valencia Community. Protection Study in Older People (EPACV). BMC Neurology, 2012, 12, 118.	0.8	2
375	Acute Lymphoblastic Leukemia. , 2016, , 145-151.		2
376	Avances en el tratamiento de la leucemia aguda linfoblástica del adulto. Medicina Clínica, 2017, 149, 119-121.	0.3	2
377	Indications and use of, and incidence of major bleeding with, antithrombotic agents in myelodysplastic syndrome. Leukemia Research, 2018, 73, 24-28.	0.4	2
378	Parada cardíaca en un paciente con leucemia mieloblástica aguda tras la primera dosis de idarubicina. Medicina Clínica, 2018, 151, 506-507.	0.3	2

#	ARTICLE	IF	CITATIONS
379	<sc>m7FLIPI</sc> and targeted sequencing in high-risk follicular lymphoma. Hematological Oncology, 2019, 37, 564-568.	0.8	2
380	Response to First Cycle Is the Major Predictor of Long-Term Response to Lenalidomide and Dexamethasone Therapy in Relapsed and Refractory Multiple Myeloma: Can We Spare Patients the Toxicity and Costs of Additional Agents?. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 585-592.e1.	0.2	2
381	Real life outcomes of patients aged ≥75 years old with acute promyelocytic leukemia: experience of the PETHEMA registry. Leukemia and Lymphoma, 2019, 60, 2720-2732.	0.6	2
382	Estudio prospectivo del seguimiento de pacientes largos supervivientes a un trasplante alogénico de progenitores hematopoyéticos. Medicina Clínica, 2021, 157, 281-284.	0.3	2
383	Gene Profiling in the Adipose Fin of Salmonid Fishes Supports Its Function as a Flow Sensor. Genes, 2020, 11, 21.	1.0	2
384	Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/TCF3-PBX1 treated with measurable residual disease-oriented protocols. British Journal of Haematology, 2021, , .	1.2	2
385	Developing a European network for adult ALL. The Hematology Journal, 2004, 5, S46-S52.	2.0	2
386	Influence of Age on Survival after a Tandem Hematopoietic Stem Cell Transplantation Procedure in Patients with Multiple Myeloma: Results of the Prospective GEM-2000 Protocol.. Blood, 2004, 104, 930-930.	0.6	2
387	Prolonged Survival in Patients with Angioimmunoblastic T-Cell Lymphoma (AIL) after High-Dose Chemotherapy and Autologous Stem Cell Transplantation (ASCT). The GELTAMO Experience.. Blood, 2005, 106, 2082-2082.	0.6	2
388	Is There a Role for Autologous Stem-Cell Transplantation (ASCT) in Peripheral T-Cell Lymphoma (PTCL)? Final Results of a Prospective Phase II Study from the GELCAB.. Blood, 2006, 108, 3070-3070.	0.6	2
389	The Prognostic Significance of Complex Karyotype in Philadelphia Chromosome-Negative (Ph <sup>-</sup> ) Acute Lymphoblastic Leukemia (ALL) in Adults Is Related with Risk Group.. Blood, 2007, 110, 3501-3501.	0.6	2
390	Gene Microdeletions in Adult and Pediatric Acute Lymphoblastic Leukemia., Blood, 2011, 118, 3539-3539.	0.6	2
391	Prevalence, Predictive Factors Therapy and Outcome of Patients with Follicular Lymphoma Refractory to First Line Immunochemotherapy. Blood, 2015, 126, 1510-1510.	0.6	2
392	Lack of impact of human immunodeficiency virus infection on the outcome of lymphoma patients transferred to the intensive care unit. Leukemia and Lymphoma, 0, , 425-430.	0.6	2
393	Allogeneic Hematopoietic Stem-Cell Transplantation (HSCT) in First Complete Remission Is Superior Compared to Chemotherapy/Autologous HSCT in Patients with Intermediate-Risk Cytogenetics Acute Myeloid Leukemia Lacking Mutations in NPM1, FLT3-ITD, and CEBPA: A Joint Study of AMLSG, Cetlam and Acute Leukemia Working Party of EBMT. Blood, 2014, 124, 324-324.	0.6	2
394	Validation of the Burkitt Lymphoma International Prognostic Index in patients treated with two prospective chemoimmunotherapy trials in Spain. Leukemia and Lymphoma, 2022, 63, 1993-1996.	0.6	2
395	Invasive aspergillosis in a patient with idiopathic thrombocytopenic purpura without underlying lung disease.. Thorax, 1992, 47, 328-328.	2.7	1
396	Assessment of quality of care in a geriatric acute care unit: A preliminary report. Aging Clinical and Experimental Research, 1995, 7, 245-246.	1.4	1

#	ARTICLE	IF	CITATIONS
397	Phenotypic analysis of blood neutrophils in a patient with chronic idiopathic neutropenia and favorable response to G-CSF treatment. <i>American Journal of Hematology</i> , 1996, 51, 96-97.	2.0	1
398	Systemic thrombotic thrombocytopenic purpura (TTP) following unrelated cord blood transplantation. <i>Leukemia and Lymphoma</i> , 2006, 47, 1173-1175.	0.6	1
399	370: Fludarabine-busulphan reduced intensity conditioning (RIC) identical sibling allogeneic stem cell transplantation (allo-SCT) in high risk acute myeloid leukemia and myelodysplastic syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 134-135.	2.0	1
400	Yâ€body study in bone marrow precursors, peripheral blood cells and alveolar macrophages for demonstration of haemopoietic engraftment in allogeneic bone marrow transplantation. <i>European Journal of Haematology</i> , 1988, 40, 424-429.	1.1	1
401	Chronic myelomonocytic leukemia diagnosed by means of mutational analysis in a patient with persistent monocytosis and tuberculosis. <i>Leukemia and Lymphoma</i> , 2013, 54, 2297-2298.	0.6	1
402	Neoplasms and infections as the main causes of death in patients in complete response to HIVâ€related nonâ€Hodgkin lymphoma in the combination antiretroviral therapy era: a study out of a series of 146 patients. <i>British Journal of Haematology</i> , 2013, 162, 289-291.	1.2	1
403	The commitment and evaluation of the quality management plan by professionals from accredited stem cell transplant centers in Spain. <i>Bone Marrow Transplantation</i> , 2014, 49, 990-992.	1.3	1
404	Leukaemic vasculitis from myelodysplastic syndrome in context. <i>Lancet, The</i> , 2015, 386, 502.	6.3	1
405	Plasmablastic lymphoma. <i>Medicina ClÃnica (English Edition)</i> , 2016, 147, 399-404.	0.1	1
406	PronÃstico similar de los linfomas transformados y los linfomas difusos de cÃ©lulas B grandes de novo en pacientes tratados con inmunquimioterapia. <i>Medicina ClÃnica</i> , 2017, 148, 243-249.	0.3	1
407	Inclusion and response criteria for clinical trials in relapsed/refractory acute lymphoblastic leukemia and usefulness of historical control trials. <i>Haematologica</i> , 2017, 102, e118-e119.	1.7	1
408	Acute lymphoblastic leukemia in adults: Steps ahead. <i>Medicina ClÃnica (English Edition)</i> , 2017, 149, 119-121.	0.1	1
409	Bone marrow<i>VEGFC</i> expression is associated with multilineage dysplasia and several prognostic markers in adult acute myeloid leukemia, but not with survival. <i>Leukemia and Lymphoma</i> , 2018, 59, 2383-2393.	0.6	1
410	Overall survival in patients with relapsed/refractory high grade B-cell lymphomas treated with gemcitabine, oxaliplatin with or without rituximab. <i>Leukemia and Lymphoma</i> , 2019, 60, 3324-3326.	0.6	1
411	Impact of previous admission to an intensive care unit on stem cell transplantation outcome. <i>Medicina ClÃnica</i> , 2020, 155, 382-387.	0.3	1
412	Tuberculosis during lenalidomide maintenance in a patient with multiple myeloma. <i>Medicina ClÃnica</i> , 2021, 156, 258-259.	0.3	1
413	AfectaciÃ³n gÃ¡strica como primera manifestaciÃ³n de infecciÃ³n por el virus varicela zÃ³ster en una paciente receptora de un trasplante alogÃ©nico de progenitores hematopoyÃ©ticos. <i>Medicina ClÃnica</i> , 2021, 157, 257-258.	0.3	1
414	Impact of In Vivo T-Cell Depletion on Outcome Following Reduced Intensity Transplantation for Hodgkin Lymphoma: Comparison between 2 Prospective Studies.. <i>Blood</i> , 2004, 104, 807-807.	0.6	1



#	ARTICLE	IF	CITATIONS
415	Autologous Stem Cell Transplant (ASCT) in HIV-1 Positive (HIV+) Hodgkin Lymphoma (HL) Patients in the HAART Era: Are Clinical Results Comparable to Those in HIV-1 Negative (HIV-) HL Patients?.. Blood, 2006, 108, 5450-5450.	0.6	1
416	Specific Intensive Chemotherapy Plus Rituximab for Advanced Burkitt's Lymphoma or Leukemia in HIV-Positive and Negative Adult Patients.. Blood, 2007, 110, 3448-3448.	0.6	1
417	A Pooled Analysis of 1,546 Patients with HIV-Associated Lymphoma: Assessment of Lymphoma-, HIV-, and Treatment-Specific Factors On Clinical Outcomes. Blood, 2012, 120, 3682-3682.	0.6	1
418	Lymphomas With MYC-Translocation Other Than Burkitt's Have An Aggressive Presentation and Poor Response To Immunochemotherapy: Study Of 34 Cases. Blood, 2013, 122, 5083-5083.	0.6	1
419	Incidence, Treatment and Prognosis of Patients with Relapsed Burkitt Lymphoma/Leukemia Treated with Specific Chemotherapy or Immunochemotherapy in Spain. Blood, 2015, 126, 2723-2723.	0.6	1
420	Response to Proteasome Inhibitors and Immunomodulatory Drugs before and after Allogeneic Transplantation in Patients with Multiple Myeloma: A Long Term Follow up Study. Blood, 2016, 128, 3436-3436.	0.6	1
421	Letter to the Editor: Interference of Schistocytes in a Platelet Count by a Beckman Coulter Counter. Laboratory Hematology: Official Publication of the International Society for Laboratory Hematology, 2006, 12, 242-243.	1.2	1
422	Management Of Elderly Patients With Diffuse Large B-Cell Lymphomas. Anti-Cancer Agents in Medicinal Chemistry, 2013, 13, 1412-1418.	0.9	1
423	Central Nervous System (CNS) Relapse in Adult Patients with Acute Lymphoblastic Leukemia (ALL): Frequency and Prognosis in 467 Patients without Cranial Irradiation for CNS Prophylaxis.. Blood, 2005, 106, 1841-1841.	0.6	1
424	Autologous Stem Cell Transplantation and Rituximab for Mantle Cell Lymphoma.. Blood, 2005, 106, 2092-2092.	0.6	1
425	Peripheral Blood Stem Cell Mobilization In Hiv Positive Patients with Lymphoma Candidates to Autologous Transplantation: Predictive Factors Analysis for Failure or Suboptimal Stem Cell Collection. Blood, 2010, 116, 2250-2250.	0.6	1
426	The Impact Of European Leukemia Net (ELN) Genetic Classification On The Outcome Of Allogeneic Stem Cell Transplantation (ALLOHCT) For Acute Myeloid Leukemia (AML) In First Complete Remission. Blood, 2013, 122, 2107-2107.	0.6	1
427	Intensive Immunochemotherapy In Patients With B-Cell Lymphoma, Unclassifiable (B-UCL), With Features Intermediate Between Diffuse Large B-Cell Lymphoma (DLBCL) and Burkitt Lymphoma (BL): A Comparison With BL Patients Treated With The Same Protocol In The Pethema-Burkimab-04 Trial. Blood, 2013, 122, 1793-1793.	0.6	1
428	Ï½DEÏ½U LO Ï½ PERDOÏ½ TOT YÏ½Ï½Ï½ L TINGA EN LA SUA SANTA GLO'RIAÏ½. ALÏ½LOMORFIA I REANA'LISI EN EL PRONOM D. Anuari De Filologia Estudis De LingÃ¼stica, 2018, , .	0.1	1
429	Estructures encapsuladores amb valor metadiscursiu en el debat parlamentari. Caplletra, 2018, , 227.	0.0	1
430	Rituximab and Specific Therapy for Patients with Burkitt's Leukemia and Lymphoma. Results of the BURKIMAB14 Trial from the Spanish Pethema and Geltamo Groups in 80 Patients. Blood, 2019, 134, 2584-2584.	0.6	1
431	Treatment of Adults with Minimal Residual Disease (MRD) Positive Acute Lymphoblastic Leukemia with Blinatumomab in a Real-World Setting: Results from the Neuf Study. Blood, 2019, 134, 2624-2624.	0.6	1
432	Eficacia de mefloquina y mirtazapina sobre la leucoencefalopatÃa multifocal progresiva en un paciente con linfoma T perifÃ©rico. Medicina ClÃnica, 2019, 153, e47-e48.	0.3	1

#	ARTICLE	IF	CITATIONS
433	Leucemia aguda linfoblástica: de la aminopterina a las células CAR T. Medicina Clínica, 2020, 154, 269-274.	0.3	1
434	Ponatinib and Chemotherapy in Young Adults with De Novo Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Results of Ponalfil Clinical Trial after Completion of Recruitment. Blood, 2020, 136, 29-30.	0.6	1
435	Early Pre-B Lymphoblastic Transformation in A Patient with Refractory Anemia. Leukemia and Lymphoma, 1991, 3, 301-303.	0.6	0
436	The role of geriatric consultation in elderly urologic patients. Aging Clinical and Experimental Research, 1995, 7, 240-241.	1.4	0
437	Seudoleucocitopenia EDTA-dependiente. Medicina Clínica, 2000, 114, 117-118.	0.3	0
438	A multivariate analysis of prognostic factors in chronic myelomonocytic leukaemia according to the FAB criteria. British Journal of Haematology, 1987, 65, 307-311.	1.2	0
439	Acute Lymphoblastic Leukemia in Adolescents and Young Adults. , 0, , .		0
440	P-275 Outcome of high-risk myelodysplastic syndrome and secondary acute leukemia treatment in patients below 75 years: CETLAM SMD-09 protocol results. Leukemia Research, 2013, 37, S146.	0.4	0
441	BAALC-associated miR-3151 is an Independent Prognostic Factor in Young Patients With Intermediate-Risk Cytogenetic Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, S122-S123.	0.2	0
442	Unique clinical implications of HIV-related lymphoma. International Journal of Hematologic Oncology, 2014, 3, 171-174.	0.7	0
443	Blinatumomab for treating acute lymphoblastic leukemia. Expert Opinion on Orphan Drugs, 2015, 3, 477-485.	0.5	0
444	Translocation (18;22)(q21;q11.2) in B-cell lymphoproliferative disorders: a report of six cases. Leukemia and Lymphoma, 2015, 56, 789-792.	0.6	0
445	Prognostic Significance of Copy Number Alterations in B-lineage Adult Acute Lymphoblastic Leukemia Patients Enrolled in Risk-adapted Protocols from the PETHEMA Group. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S173-S174.	0.2	0
446	Copy Number Alterations in patients with mature B (Burkitt-type) acute lymphoblastic leukaemia treated with specific immunochemotherapy. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S174.	0.2	0
447	Copy number alterations in adult patients with mature B acute lymphoblastic leukemia treated with specific immunochemotherapy. Medicina Clínica (English Edition), 2016, 147, 488-491.	0.1	0
448	Utilidad del lavado broncoalveolar y la citometría de flujo en pacientes con hemopatías malignas e insuficiencia respiratoria. Medicina Clínica, 2017, 148, 297-302.	0.3	0
449	Similar prognosis of transformed and de novo diffuse large B-cell lymphomas in patients treated with immunochemotherapy. Medicina Clínica (English Edition), 2017, 148, 243-249.	0.1	0
450	Use of MRD for Selection of Post Remission Therapy in Adult All Management. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S69-S71.	0.2	0

#	ARTICLE	IF	CITATIONS
451	WHOLE-GENOME SEQUENCING OF NODAL MARGINAL ZONE LYMPHOMAS IDENTIFIES RECURRENT MOLECULAR LESIONS IN GENES INVOLVED IN CHROMATIN REMODELLING AND NOTCH SIGNALLING. Hematological Oncology, 2017, 35, 149-149.	0.8	0
452	The influence of antiretroviral therapy on clinical aspects of HIV-related lymphoma. International Journal of Hematologic Oncology, 2017, 6, 35-38.	0.7	0
453	Tratamiento de rescate de pacientes con leucemia aguda en recaída después de un primer trasplante alogénico de progenitores hematopoyéticos. Medicina Clínica, 2018, 151, 376-377.	0.3	0
454	Segundas neoplasias en pacientes adultos receptores de un trasplante de progenitores hematopoyéticos. Medicina Clínica, 2018, 150, 421-427.	0.3	0
455	The case for lymphoma-specific survival. Expert Review of Hematology, 2018, 11, 263-264.	1.0	0
456	A step ahead in Philadelphia chromosome-positive acute lymphoblastic leukaemia. Lancet Haematology, 2018, 5, e602-e603.	2.2	0
457	Ponatinib vs Imatinib with Reduced-Intensity Chemotherapy in Patients with Newly Diagnosed Philadelphia Chromosome-Positive (Ph+) ALL: PhALLCON Study. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S194.	0.2	0
458	Enfermedad del injerto contra el receptor tras infección por Rickettsia conorii inducida por la picadura de una garrapata. Medicina Clínica, 2019, 152, 119-120.	0.3	0
459	Tratamiento adaptado a la gestación en una paciente con linfoma de Burkitt. Medicina Clínica, 2020, 154, 470-471.	0.3	0
460	Who Should Receive an Allogeneic Transplant in First Complete Remission?. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, S48-S51.	0.2	0
461	Sarcoma granulocítico: estudio de dos casos mediante secuenciación masiva. Medicina Clínica, 2021, 156, 306-307.	0.3	0
462	Leucemia aguda mieloblástica con reordenamiento de MOZ/CBP. Medicina Clínica, 2004, 122, 639-639.	0.3	0
463	Intento de suicidio mediante la inyección subcutánea de mercurio. Medicina Clínica, 2004, 123, 557-557.	0.3	0
464	Germline Polymorphisms Provide Strong Prognostic Information in Intermediate Risk Acute Myeloblastic Leukemia (AML).. Blood, 2004, 104, 398-398.	0.6	0
465	Outcome and Prognostic Factors in Patients with Hematological Malignancy That Are Admitted to the Intensive Care Unit.. Blood, 2004, 104, 5285-5285.	0.6	0
466	Secondary Malignancies after Autologous Stem Cell Transplantation for Hodgkin's Lymphoma: Incidence and Analysis of Risk Factors.. Blood, 2004, 104, 60-60.	0.6	0
467	Allogeneic Transplant with Reduced Intensity Conditioning Regimens (RIC) Could Reverse Poor Prognosis of Unmutated IgH, 11q- or 17p- Abnormalities in B-Cell Chronic Lymphocytic Leukemia (B-CLL).. Blood, 2004, 104, 2319-2319.	0.6	0
468	Rituximab and Stem Cell Transplantation Produces Durable Remissions in Mantle Cell Lymphoma.. Blood, 2004, 104, 1390-1390.	0.6	0

#	ARTICLE	IF	CITATIONS
469	Non Myeloablative Transplant in Patients with Indolent Non-Hodgkinâ€™s Lymphoma (NHL): Results of Two Prospectives Multicenter Trials.. Blood, 2004, 104, 2318-2318.	0.6	0
470	Treatment with Rituximab, CHOP and Highly Active Antiretroviral Therapy (HAART) in AIDS-Related Diffuse Large B-Cell Lymphomas (DLBCL). Study of 60 Patients.. Blood, 2005, 106, 774-774.	0.6	0
471	High-Dose Therapy/Stem Cell Support (HDT), Including Tandem Transplant, for Primary Refractory Multiple Myeloma (MM): Results from the Spanish Myeloma Group (PETHEMA/GEM) in 49 Patients.. Blood, 2005, 106, 5472-5472.	0.6	0
472	Use of Granulocyte Colony-Stimulating Factor (G-CSF) Together with Induction and Intensification Chemotherapy (CT) in Adults with Primary Acute Myeloid Leukemia (AML).. Blood, 2005, 106, 1855-1855.	0.6	0
473	Scoring System To Predict the Risk of Early Death during Induction Chemotherapy for Primary Acute Myeloid Leukemia (AML).. Blood, 2006, 108, 1972-1972.	0.6	0
474	Long Remission Are Possible after Non Myeloablative Transplant in Patients with Follicular Non-Hodgkinâ€™s Lymphoma (NHL): Results of Two Prospectives Multicenter Trials.. Blood, 2006, 108, 3024-3024.	0.6	0
475	Fludarabine and Busuphan (Flu-Bu) as Reduced Intensity-Conditioning (RIC) Regimen in HLA-Identical Sibling Allogeneic Hematopoietic Stem Transplantation (Allo-SCT) for Myeloid Malignancies. Results of a Prospective Multicenter Study.. Blood, 2006, 108, 5363-5363.	0.6	0
476	Comparison of Immunohistochemical (IHC) Expression Profile and Prognosis in 98 Patients with Diffuse Large B Cell Non-Hodgkinâ€™s Lymphoma (DLBCL) with and without Human Immunodeficiency Virus (HIV) Infection.. Blood, 2007, 110, 4403-4403.	0.6	0
477	Non Myeloablative Allogeneic Related Transplant in Patients with Aggressive B Cell Lymphoma: Results of Two Multicenter Spanish Trials. The GELTAMO Group.. Blood, 2007, 110, 5053-5053.	0.6	0
478	Preliminary Results of the Combination Rituximab, Fludarabine, Cyclophosphamide and Mitoxantrone (R-FCM) Followed by Rituximab Maintenance in Previously Untreated Chronic Lymphocytic Leukemia (CLL).. Blood, 2007, 110, 626-626.	0.6	0
479	Prognostic significance of mutations of nucleophosmin (NPM1) gene and internal tandem duplication of FLT3 gene (FLT3 ITD) in acute myeloid leukemia (AML) with normal karyotype. Journal of Clinical Oncology, 2008, 26, 7024-7024.	0.8	0
480	El proceso editorial. , 2010, , 309-326.		0
481	Validation of the European Leukemia Net (ELN) Genetic Classification of Acute Myeloid Leukemia: Inclusion of Monosomal Karyotype Improves Prognostic Discrimination. Blood, 2010, 116, 1712-1712.	0.6	0
482	Graft-Failure After Allogeneic Stem Cell Transplantation. Outcome and Prognostic Factors in 80 Patients. Blood, 2011, 118, 1936-1936.	0.6	0
483	Unrelated Cord Blood Transplantation Using Myeloablative Conditioning Regimen for Adults with Acute Myeloid Leukemia in First Complete Remission. A Survey by EUROCORD and the Acute Leukemia Working Party of the EBMT. Blood, 2011, 118, 836-836.	0.6	0
484	ARL-IPI - A New Prognostic Score for AIDS-Related Lymphomas in the Rituximab Era. Blood, 2012, 120, 1564-1564.	0.6	0
485	Clinical and Biological Characteristics According to the Burden of JAK2V617F Mutated Allele in BCR-ABL Negative MPNs. Blood, 2012, 120, 1437-1437.	0.6	0
486	Feasibility of the AMLprofilerâ„¢ (Skyline array) in Patient Risk-Stratification in a Multicenter Trial. Comparison with the Standard Approach. Blood, 2012, 120, 4813-4813.	0.6	0

#	ARTICLE	IF	CITATIONS
487	Prognostic Value of Complex Karyotype and Monosomal Karyotype in Patients with Adult Acute Lymphoblastic Leukemia Treated with Risk-Adapted Protocols. <i>Blood</i> , 2012, 120, 4785-4785.	0.6	0
488	Prognostic Impact of the Levels of Expression of Cell Surface Proteins Commonly Expressed by Blasts and Hematopoietic Precursor Cells in De Novo AML Patients: A Report From the Spanish Cetlam Study Group. <i>Blood</i> , 2012, 120, 1452-1452.	0.6	0
489	Characterization of Cytogenetic Abnormalities and Mutations in ASXL1, SRSF2, CBL and JAK2 Genes in Chronic Myelomonocytic Leukemia. <i>Blood</i> , 2012, 120, 4809-4809.	0.6	0
490	Prognostic Factors in Patients with HIV-Associated Hodgkin Lymphoma: An Analysis of 199 Cases. <i>Blood</i> , 2012, 120, 1528-1528.	0.6	0
491	Are Outcomes After Myeloablative Conditioning Regimen in Double Cord Blood Transplantation (UCBT) Better Than Single UCBT for Adults with Acute Leukemia in Remission?.. <i>Blood</i> , 2012, 120, 3083-3083.	0.6	0
492	Clinical and Biological Features Of Monoclonal B-Cell Lymphocytosis In Patients Referred To Hospital. <i>Blood</i> , 2013, 122, 5298-5298.	0.6	0
493	Prognostic Significance Of Copy Number Alterations In B-Lineage Adult Acute Lymphoblastic Leukemia Patients Enrolled In Risk-Adapted Protocols From The Pethema Group. <i>Blood</i> , 2013, 122, 2556-2556.	0.6	0
494	BAALC-Associated Mir-3151 Is An Independent Prognostic Factor In Younger Patients With Intermediate-Risk Cytogenetic Acute Myeloid Leukemia. <i>Blood</i> , 2013, 122, 2577-2577.	0.6	0
495	Differences In Clinical-Biological Features and Outcome Between Diffuse Large B-Cell Lymphomas Of HIV-Infected and Non-HIV-Infected Patients Treated With RCHOP In The CART Era. <i>Blood</i> , 2013, 122, 1815-1815.	0.6	0
496	A randomized double-blind phase III pivotal study of febuxostat (FEB) versus allopurinol (ALL) in the prevention of tumor lysis syndrome (TLS): Florence study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9641-9641.	0.8	0
497	CNS involvement in patients with AIDS-related lymphomas.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8570-8570.	0.8	0
498	Advanced Stage Hodgkin's Lymphoma Has More Aggressive Characteristics but Similar Outcome in HIV-Infected Than in HIV-Negative Patients in the Combination Antiretroviral Therapy Era. <i>Blood</i> , 2014, 124, 4435-4435.	0.6	0
499	Hidden DNA Copy Number Alterations and Mutations in IKZF1, TP53, CRLF2 and JAK2 Genes Are Associated with a Poor Prognosis in B-Progenitor Acute Lymphoblastic Leukemia. <i>Blood</i> , 2014, 124, 1082-1082.	0.6	0
500	Epstein-Barr Virus Viral Loads and Serum Free Light Chains Levels Are Diagnostic Markers of Lymphoma in HIV-Infected Patients. <i>Blood</i> , 2014, 124, 1697-1697.	0.6	0
501	Decision Driven Factors for Allopurinol Dosage in Tumor Lysis Syndrome Prophylaxis: The European Experience of the Florence Pivotal Study. <i>Blood</i> , 2014, 124, 5979-5979.	0.6	0
502	The LincRNA HOTAIRM1, Located in the HOXA genomic Region, impacts Prognosis in Acute Myeloid Leukemia and Is Associated with a Distinctive microRNA Signature. <i>Blood</i> , 2014, 124, 1003-1003.	0.6	0
503	Genetic Markers Add Significant Prognostic Information to Age and WBC Count in High-Risk, Ph-Negative, B-Precursor Adult Acute Lymphoblastic Leukemia (ALL): Study of 96 Patients Treated According to Risk-Adapted Protocols from the Pethema Group. <i>Blood</i> , 2014, 124, 3798-3798.	0.6	0
504	Frequency and Prognosis of JAK2 V617F, Calr, MPL and ASXL1 Mutations in Primary Myelofibrosis. <i>Blood</i> , 2014, 124, 5562-5562.	0.6	0

#	ARTICLE	IF	CITATIONS
505	Favorable Outcome of Older Patients with AML and a Favorable Genotype NPM1mut FLT3-ITD Treated with Intensive Chemotherapy: A Subgroup Analysis of Cetlam Protocol 2003 & 2012. Blood, 2015, 126, 2511-2511.	0.6	0
506	Prognostic Impact of MLL Partial Tandem Duplication in Acute Myeloid Leukemia of Intermediate Cytogenetic Risk: A Subgroup Analysis of Cetlam Protocol 2003 & 2012. Blood, 2015, 126, 2514-2514.	0.6	0
507	Allogeneic Hematopoietic Cell Transplantation (HCT) for Advanced Mycosis Fungoides and Sezary Syndrome (MF/SS): Impact of Increasing the Use of Unrelated Donors (UD) - the EBMT Lymphoma Working Party Experience. Blood, 2015, 126, 4403-4403.	0.6	0
508	Gene Rearrangements and Other Molecular Features in Aggressive B-Cell Lymphomas of Patients with and without HIV-Infection. Blood, 2015, 126, 3874-3874.	0.6	0
509	The Risk of Sinusoidal Obstruction Syndrome (SOS) in Allogeneic Hematopoietic Stem Cell Transplantation after Prior Gemtuzumab Ozogamicin Treatment: A Retrospective Study on Behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood, 2015, 126, 3110-3110.	0.6	0
510	Second Malignancies. , 2016, , 235-237.		0
511	Frequency and Prognostic Significance of the Presence of Additional Cytogenetic Abnormalities (ACA) to the Philadelphia (Ph) Chromosome in Young Adults with ACUTE Lymphoblastic Leukemia (ALL) Treated with the ALL Ph08 Trial from the Pethema Group. Blood, 2016, 128, 1602-1602.	0.6	0
512	Genomic Characterization of Paired Diagnosis and Relapse Samples from Adult Patients with B-Cell Precursor Acute Lymphoblastic Leukemia. Blood, 2016, 128, 5281-5281.	0.6	0
513	Post-transplantation long-term outcomes in 43 HIV-positive patients affected by high-risk or relapsed lymphoma.. Journal of Clinical Oncology, 2017, 35, 121-121.	0.8	0
514	Introducci3 al monogr3fic 3«L3encapsulaci3 l3xica: cohesi3, coher3ncia i metadiscurs3». Caplletra, 2018, , 105.	0.0	0
515	Human Immunodeficiency Virus-Related Lymphomas. Technik Im Fokus, 2019, , 177-188.	0.2	0
516	Neoplasia de c3lulas dendr3ticas bl3jsticas plasmacitoides. Estudio de tres casos. Medicina Cl3nica, 2020, 154, 524-525.	0.3	0
517	Validation of New International Prognostic Scores, Including Baseline Peripheral Blood Variables, in Patients with Diffuse Large B-Cell Lymphoma and HIV Infection Treated with R-CHOP and Combined Antiretroviral Therapy. Retrospective Study from Spanish Lymphoma Group Geltamo. Blood, 2021, 138, 2497-2497.	0.6	0
518	Frequency, Clinical Characteristics and Outcome of Adult Patients with Acute Lymphoblastic Leukemia (ALL) and COVID-19 in Spain: Results of a Survey from Pethema and Geth Groups. Blood, 2020, 136, 19-19.	0.6	0
519	Outcome of Adults with Relapsed T-Cell Acute Lymphoblastic Leukemia (T-ALL) Included in Minimal Residual Disease (MRD)-Oriented Trials. Blood, 2020, 136, 6-7.	0.6	0
520	Anticuerpos monoclonales en el tratamiento de primera l3nea de la leucemia aguda linfobl3jstica en adultos: un paso adelante. Medicina Cl3nica, 2022, 158, 476-476.	0.3	0
521	Persistent fever after recovery from granulocytopenia in acute leukemia. Archives of Internal Medicine, 1988, 148, 2509-2509.	4.3	0
522	Erythema nodosum as a presenting feature of T-cell-rich B-cell lymphoma. Annals of Hematology, 1995, 70, 107-108.	0.8	0

#	ARTICLE	IF	CITATIONS
523	Occlusion of the superior mesenteric artery in a patient with Polycythemia vera: Resolution with percutaneous transluminal angioplasty. <i>Annals of Hematology</i> , 1996, 72, 89-91.	0.8	0
524	Monoclonal antibodies in frontline therapy of adult acute lymphoblastic leukemia: A step ahead. <i>Medicina Clínica (English Edition)</i> , 2022, 158, 476-476.	0.1	0